<?xml version="1.0" encoding="UTF-8"?>
<COCHRANE_REVIEW TYPE="INTERVENTION" REVMAN_VERSION="5" ID="000000000000000000" VERSION_NO="2.9" STAGE="R" STATUS="A">
<COVER_SHEET>
<TITLE>Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis [Data only. When citing this record quote "Cochrane Database of Systematic Reviews 2015, Issue 9".]</TITLE>
<CONTACT>
<PERSON ID="6231" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Graziella</FIRST_NAME>
<MIDDLE_INITIALS />
<LAST_NAME>Filippini</LAST_NAME>
<SUFFIX />
<POSITION />
<EMAIL_1>gfilippini@istituto-besta.it</EMAIL_1>
<EMAIL_2 />
<URL>http://www.msg.cochrane.org</URL>
<MOBILE_PHONE />
<ADDRESS>
<DEPARTMENT>Scientific Direction</DEPARTMENT>
<ORGANISATION>Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta</ORGANISATION>
<ADDRESS_1>via Celoria, 11</ADDRESS_1>
<ADDRESS_2 />
<CITY>Milano</CITY>
<ZIP>20133</ZIP>
<REGION />
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 02 23942381</PHONE_1>
<PHONE_2 />
<FAX_1>+39 02 23942713</FAX_1>
<FAX_2 />
</ADDRESS>
<FOOTNOTE />
</PERSON>
</CONTACT>
<CREATORS>
<PERSON ID="z1301290905079041769940823613591" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Irene</FIRST_NAME>
<MIDDLE_INITIALS />
<LAST_NAME>Tramacere</LAST_NAME>
<SUFFIX />
<POSITION>Statistician</POSITION>
<EMAIL_1>irene.tramacere@istituto-besta.it</EMAIL_1>
<EMAIL_2 />
<URL />
<MOBILE_PHONE />
<ADDRESS>
<DEPARTMENT>Neuroepidemiology Unit</DEPARTMENT>
<ORGANISATION>Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta</ORGANISATION>
<ADDRESS_1>Via Giovanni Celoria, 11</ADDRESS_1>
<ADDRESS_2 />
<CITY>Milano</CITY>
<ZIP>20133</ZIP>
<REGION />
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 02 23942102</PHONE_1>
<PHONE_2 />
<FAX_1>+39 03 23942713</FAX_1>
<FAX_2 />
</ADDRESS>
<FOOTNOTE />
</PERSON>
<PERSON ID="89374802568313722654100427113932" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Cinzia</FIRST_NAME>
<MIDDLE_INITIALS />
<LAST_NAME>Del Giovane</LAST_NAME>
<SUFFIX />
<POSITION />
<EMAIL_1>cinzia.delgiovane@unimore.it</EMAIL_1>
<EMAIL_2 />
<URL />
<MOBILE_PHONE />
<ADDRESS>
<DEPARTMENT>Italian Cochrane Centre, Department of Diagnostic, Clinical and Public Health Medicine</DEPARTMENT>
<ORGANISATION>University of Modena and Reggio Emilia</ORGANISATION>
<ADDRESS_1 />
<ADDRESS_2 />
<CITY>Modena</CITY>
<ZIP />
<REGION />
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 059 4223032</PHONE_1>
<PHONE_2 />
<FAX_1 />
<FAX_2 />
</ADDRESS>
<FOOTNOTE />
</PERSON>
<PERSON ID="17174" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Georgia</FIRST_NAME>
<MIDDLE_INITIALS />
<LAST_NAME>Salanti</LAST_NAME>
<SUFFIX />
<POSITION>Assistant Professor</POSITION>
<EMAIL_1>georgia.salanti@googlemail.com</EMAIL_1>
<EMAIL_2 />
<URL />
<MOBILE_PHONE>+30 6971863717</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Hygiene and Epidemiology</DEPARTMENT>
<ORGANISATION>University of Ioannina School of Medicine</ORGANISATION>
<ADDRESS_1>Medical School Campus</ADDRESS_1>
<ADDRESS_2>University of Ioannina</ADDRESS_2>
<CITY>Ioannina</CITY>
<ZIP>45110</ZIP>
<REGION />
<COUNTRY CODE="GR">Greece</COUNTRY>
<PHONE_1>+30 26510 07757</PHONE_1>
<PHONE_2 />
<FAX_1>+30 26510 07853</FAX_1>
<FAX_2 />
</ADDRESS>
<FOOTNOTE />
</PERSON>
<PERSON ID="11485" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Roberto</FIRST_NAME>
<MIDDLE_INITIALS />
<LAST_NAME>D'Amico</LAST_NAME>
<SUFFIX />
<POSITION>Assistant professor</POSITION>
<EMAIL_1>roberto.damico@unimore.it</EMAIL_1>
<EMAIL_2 />
<URL />
<MOBILE_PHONE>+39 3316213042</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Italian Cochrane Centre, Department of Diagnostic, Clinical and Public Health Medicine</DEPARTMENT>
<ORGANISATION>University of Modena and Reggio Emilia</ORGANISATION>
<ADDRESS_1>Via del Pozzo 71</ADDRESS_1>
<ADDRESS_2 />
<CITY>Modena</CITY>
<ZIP>41124</ZIP>
<REGION />
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 059 4223865</PHONE_1>
<PHONE_2 />
<FAX_1>+39 059 4223235</FAX_1>
<FAX_2 />
</ADDRESS>
<FOOTNOTE />
</PERSON>
<PERSON ID="6231" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Graziella</FIRST_NAME>
<MIDDLE_INITIALS />
<LAST_NAME>Filippini</LAST_NAME>
<SUFFIX />
<POSITION />
<EMAIL_1>gfilippini@istituto-besta.it</EMAIL_1>
<EMAIL_2 />
<URL>http://www.msg.cochrane.org</URL>
<MOBILE_PHONE />
<ADDRESS>
<DEPARTMENT>Scientific Direction</DEPARTMENT>
<ORGANISATION>Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta</ORGANISATION>
<ADDRESS_1>via Celoria, 11</ADDRESS_1>
<ADDRESS_2 />
<CITY>Milano</CITY>
<ZIP>20133</ZIP>
<REGION />
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 02 23942381</PHONE_1>
<PHONE_2 />
<FAX_1>+39 02 23942713</FAX_1>
<FAX_2 />
</ADDRESS>
<FOOTNOTE />
</PERSON>
</CREATORS>
<DATES>
<UP_TO_DATE>
<DATE DAY="" MONTH="" YEAR="" />
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="" MONTH="" YEAR="" />
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR="" />
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR="" />
<REVIEW_PUBLISHED ISSUE="" YEAR="" />
<LAST_CITATION_ISSUE ISSUE="" YEAR="" />
</DATES>
<WHATS_NEW />
<HISTORY />
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES />
<EXTERNAL_SOURCES />
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO" />
<KEYWORDS />
</COVER_SHEET>
<MAIN_TEXT>
<SUMMARY>
<TITLE>Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis</TITLE>
<SUMMARY_BODY>
<P>
<B>Background</B>
</P>
<P>Different therapeutic strategies are available for the treatment of people with relapsing-remitting multiple sclerosis (RRMS), including immunomodulators, immunosuppressants, and biologics. Although there is consensus that these therapies may reduce the frequency of relapses, their relative benefit (effectiveness compared to each other) in delaying new relapses or disability worsening remains unclear due to the limited number of direct comparison studies (i.e. studies comparing two or more active agents with each other).</P>
<P>
<B>Objectives</B>
</P>
<P>We aimed to assess and rank the benefit from and the extent of adverse events associated with 15 drugs, i.e. interferon beta-1b, interferon beta-1a (Avonex, Rebif), glatiramer acetate, natalizumab, mitoxantrone, fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab, pegylated interferon beta-1a, daclizumab, laquinimod, azathioprine, and immunoglobulins.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We included 39 studies up to September 2014 in this review, comprising a total of 25,113 participants suffering from RRMS. The majority of the included studies were short-term, with a median duration of 24 months.</P>
<P>
<B>Key results and quality of the evidence</B>
</P>
<P>For preventing relapses, alemtuzumab, natalizumab, and fingolimod are more effective than the other drugs, based on moderate to high quality evidence.</P>
<P>For preventing irreversible disability worsening, insufficient evidence is currently available.</P>
<P>Almost all of the agents included in this review were associated with a higher proportion of participants who withdrew due to any adverse event compared to placebo.</P>
<P>It is worth noting the following:</P>
<P>- The benefit of all of these treatments beyond two years is uncertain and this is a very relevant issue for people with a lifelong disease such as multiple sclerosis, who will possibly need long-term treatments.</P>
<P>- Safety data from these short-term studies are scanty, poorly reported and cannot provide enough evidence for us to obtain a reliable risk profile of the treatments included in this review.</P>
<P>- Most of the included studies were sponsored by pharmaceutical companies and this is a known potential source of bias.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P />
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P />
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P />
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P />
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P />
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P />
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P />
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P />
<CONDITION>
<P />
</CONDITION>
<INTERVENTION>
<P />
</INTERVENTION>
<THEORY>
<P />
</THEORY>
<IMPORTANCE>
<P />
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P />
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P />
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P />
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P />
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P />
<CRIT_OUTCOMES_PRIMARY>
<P />
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY>
<P />
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P />
<ELECTRONIC_SEARCHES>
<P />
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES>
<P />
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P />
<STUDY_SELECTION>
<P />
</STUDY_SELECTION>
<DATA_EXTRACTION>
<P />
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT>
<P />
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES>
<P />
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS>
<P />
</UNIT_OF_ANALYSIS>
<MISSING_DATA>
<P />
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT>
<P />
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT>
<P />
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS>
<P />
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS>
<P />
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS>
<P />
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P />
<SEARCH_RESULTS>
<P />
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR>
<P />
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR>
<P />
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P />
<ALLOCATION>
<P />
</ALLOCATION>
<BLINDING>
<P />
</BLINDING>
<EXCLUSIONS>
<P />
</EXCLUSIONS>
<SELECTIVE_REPORTING>
<P />
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES>
<P />
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P />
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P />
<SUMMARY_OF_RESULTS>
<P />
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS>
<P />
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE>
<P />
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES>
<P />
</POTENTIAL_BIASES>
<AGREEMENT>
<P />
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P />
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P />
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P />
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P />
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P />
</CONTRIBUTIONS>
<PRO_REV_DIFF>
<P />
</PRO_REV_DIFF>
<PUBLIC_NOTES>
<P />
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Achiron-1998" NAME="Achiron 1998" YEAR="1998">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ADVANCE-2014" NAME="ADVANCE 2014" YEAR="2014">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-AFFIRM-2006" NAME="AFFIRM 2006" YEAR="2006">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ALLEGRO-2012" NAME="ALLEGRO 2012" YEAR="2012">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-BECOME-2009" NAME="BECOME 2009" YEAR="2009">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-BEYOND-2009" NAME="BEYOND 2009" YEAR="2009">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bornstein-1987" NAME="Bornstein 1987" YEAR="1987">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-BRAVO-2014" NAME="BRAVO 2014" YEAR="2014">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CAMMS223-2008" NAME="CAMMS223 2008" YEAR="2008">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CARE_x002d_MS-I-2012" NAME="CARE-MS I 2012" YEAR="2012">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CARE_x002d_MS-II-2012" NAME="CARE-MS II 2012" YEAR="2012">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CombiRx-2013" NAME="CombiRx 2013" YEAR="2013">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Comi-2001" NAME="Comi 2001" YEAR="2001">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CONFIRM-2012" NAME="CONFIRM 2012" YEAR="2012">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DEFINE-2012" NAME="DEFINE 2012" YEAR="2012">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Etemadifar-2007" NAME="Etemadifar 2007" YEAR="2007">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EVIDENCE-2007" NAME="EVIDENCE 2007" YEAR="2007">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fazekas-1997" NAME="Fazekas 1997" YEAR="1997">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fazekas-2008" NAME="Fazekas 2008" YEAR="2008">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-FREEDOMS-2010" NAME="FREEDOMS 2010" YEAR="2010">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-FREEDOMS-II-2014" NAME="FREEDOMS II 2014" YEAR="2014">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-GALA-2013" NAME="GALA 2013" YEAR="2013">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goodkin-1991" NAME="Goodkin 1991" YEAR="1991">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-IFNB-MS-Group-1993" NAME="IFNB MS Group 1993" YEAR="1993">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-INCOMIN-2002" NAME="INCOMIN 2002" YEAR="2002">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-1995" NAME="Johnson 1995" YEAR="1995">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koch_x002d_Henriksen-2006" NAME="Koch-Henriksen 2006" YEAR="2006">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewanska-2002" NAME="Lewanska 2002" YEAR="2002">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MAIN-TRIAL" NAME="MAIN TRIAL" YEAR="2014">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Millefiorini-1997" NAME="Millefiorini 1997" YEAR="1997">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MSCRG-1996" NAME="MSCRG 1996" YEAR="1996">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-OWIMS-1999" NAME="OWIMS 1999" YEAR="1999">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PRISMS-1998" NAME="PRISMS 1998" YEAR="1998">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-REGARD-2008" NAME="REGARD 2008" YEAR="2008">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SELECT-2013" NAME="SELECT 2013" YEAR="2013">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TEMSO-2011" NAME="TEMSO 2011" YEAR="2011">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TENERE-2014" NAME="TENERE 2014" YEAR="2013">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TOWER-2014" NAME="TOWER 2014" YEAR="2014">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TRASFORMS-2010" NAME="TRASFORMS 2010" YEAR="2010">
<IDENTIFIERS />
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES />
<AWAITING_STUDIES />
<ONGOING_STUDIES />
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES />
<OTHER_VERSIONS_REFERENCES />
<PENDING_REFERENCES />
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Achiron-1998">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-ADVANCE-2014">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-AFFIRM-2006">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-ALLEGRO-2012">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-BECOME-2009">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-BEYOND-2009">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bornstein-1987">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-BRAVO-2014">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-CAMMS223-2008">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-CARE_x002d_MS-I-2012">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-CARE_x002d_MS-II-2012">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-CombiRx-2013">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Comi-2001">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-CONFIRM-2012">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-DEFINE-2012">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Etemadifar-2007">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-EVIDENCE-2007">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Fazekas-1997">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Fazekas-2008">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-FREEDOMS-2010">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-FREEDOMS-II-2014">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-GALA-2013">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Goodkin-1991">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-IFNB-MS-Group-1993">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-INCOMIN-2002">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Johnson-1995">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Koch_x002d_Henriksen-2006">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lewanska-2002">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-MAIN-TRIAL">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Millefiorini-1997">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-MSCRG-1996">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-OWIMS-1999">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-PRISMS-1998">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-REGARD-2008">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-SELECT-2013">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-TEMSO-2011">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-TENERE-2014">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-TOWER-2014">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-TRASFORMS-2010">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P />
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES>
<P />
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES>
<P />
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES>
<P />
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS />
<SOF_TABLES />
<ADDITIONAL_TABLES />
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Treatment benefit within pairwise comparisons</NAME>
<DICH_OUTCOME CHI2="137.9615544429639" CI_END="0.8175361357017771" CI_START="0.753868348169228" CI_STUDY="95" CI_TOTAL="95" DF="30" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7850570783007771" ESTIMABLE="YES" EVENTS_1="4301" EVENTS_2="3132" I2="78.25481155157424" I2_Q="78.51719232536836" ID="CMP-001.01" LOG_CI_END="-0.0874930421061553" LOG_CI_START="-0.12270449054373174" LOG_EFFECT_SIZE="-0.10509876632494354" METHOD="MH" NO="1" P_CHI2="8.881784197001252E-16" P_Q="1.8475032614873044E-10" P_Z="1.2721285482990731E-31" Q="83.78793066818551" RANDOM="YES" SCALE="10.0" SORT_BY="WEIGHT" STUDIES="29" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.03416984835840908" TOTALS="SUB" TOTAL_1="12376" TOTAL_2="6778" WEIGHT="1900.0" Z="11.700160371514574">
<NAME>Comparisons for relapses over 12 months</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3649206092239712E-30" CI_END="1.0544090665435144" CI_START="0.7264928242938471" DF="0" EFFECT_SIZE="0.8752260397830018" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="91" I2="100.0" ID="CMP-001.01.01" LOG_CI_END="0.023009131632416902" LOG_CI_START="-0.13876867095298842" LOG_EFFECT_SIZE="-0.05787976966028577" NO="1" P_CHI2="0.0" P_Z="0.16078229733444477" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="143" WEIGHT="100.0" Z="1.4024453559720726">
<NAME>Interferon beta-1a (Avonex) versus placebo</NAME>
<DICH_DATA CI_END="1.0544090665435144" CI_START="0.7264928242938471" EFFECT_SIZE="0.8752260397830018" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="91" LOG_CI_END="0.023009131632416902" LOG_CI_START="-0.13876867095298842" LOG_EFFECT_SIZE="-0.05787976966028577" ORDER="184" O_E="0.0" SE="0.09502908205170525" STUDY_ID="STD-MSCRG-1996" TOTAL_1="158" TOTAL_2="143" VAR="0.009030526435589728" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.175913515275376" CI_END="1.1881946441870446" CI_START="0.6601445004188313" DF="1" EFFECT_SIZE="0.8856523921873567" ESTIMABLE="YES" EVENTS_1="357" EVENTS_2="213" I2="87.76895085629684" ID="CMP-001.01.02" LOG_CI_END="0.07488759045334713" LOG_CI_START="-0.18036099041924866" LOG_EFFECT_SIZE="-0.052736699982950795" NO="2" P_CHI2="0.0042450609822037855" P_Z="0.4180016234806976" STUDIES="2" TAU2="0.039571791421910724" TOTAL_1="566" TOTAL_2="287" WEIGHT="100.0" Z="0.8098931032385999">
<NAME>Interferon beta-1a (Rebif) versus placebo</NAME>
<DICH_DATA CI_END="1.233411369988687" CI_START="0.8706376135236693" EFFECT_SIZE="1.0362694300518134" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="65" LOG_CI_END="0.09110794757705935" LOG_CI_START="-0.06016257426464461" LOG_EFFECT_SIZE="0.015472686656207395" ORDER="185" O_E="0.0" SE="0.08885705333097654" STUDY_ID="STD-OWIMS-1999" TOTAL_1="193" TOTAL_2="100" VAR="0.00789557592666401" WEIGHT="47.359458816564214" />
<DICH_DATA CI_END="0.8581141833807384" CI_START="0.6890468517394072" EFFECT_SIZE="0.7689479023259184" ESTIMABLE="YES" EVENTS_1="227" EVENTS_2="148" LOG_CI_END="-0.06645491971215133" LOG_CI_START="-0.16175124723589532" LOG_EFFECT_SIZE="-0.11410308347402333" ORDER="186" O_E="0.0" SE="0.05597753451187635" STUDY_ID="STD-PRISMS-1998" TOTAL_1="373" TOTAL_2="187" VAR="0.003133484370028308" WEIGHT="52.64054118343579" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.884553683041208" CI_END="0.9512856375570925" CI_START="0.6631664858213266" DF="3" EFFECT_SIZE="0.7942674318332821" ESTIMABLE="YES" EVENTS_1="488" EVENTS_2="416" I2="56.42419046873102" ID="CMP-001.01.03" LOG_CI_END="-0.021689060150955185" LOG_CI_START="-0.1783774296692392" LOG_EFFECT_SIZE="-0.10003324491009714" NO="3" P_CHI2="0.07566996629988099" P_Z="0.012329634880924126" STUDIES="4" TAU2="0.017407498894973214" TOTAL_1="1447" TOTAL_2="969" WEIGHT="100.0" Z="2.50256681951862">
<NAME>Glatiramer acetate versus placebo</NAME>
<DICH_DATA CI_END="0.717155999350862" CI_START="0.18926714988791998" EFFECT_SIZE="0.3684210526315789" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="19" LOG_CI_END="-0.14438636415353348" LOG_CI_START="-0.7229247577236109" LOG_EFFECT_SIZE="-0.43365556093857216" ORDER="187" O_E="0.0" SE="0.33983631619429855" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="25" VAR="0.11548872180451125" WEIGHT="6.374352792385718" />
<DICH_DATA CI_END="1.1546304197129227" CI_START="0.6985786965628394" EFFECT_SIZE="0.898109243697479" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="64" LOG_CI_END="0.06244299516801054" LOG_CI_START="-0.15578466248061393" LOG_EFFECT_SIZE="-0.04667083365630169" ORDER="188" O_E="0.0" SE="0.1281880063471293" STUDY_ID="STD-Comi-2001" TOTAL_1="119" TOTAL_2="120" VAR="0.01643216497125166" WEIGHT="25.03356412942326" />
<DICH_DATA CI_END="1.0508294966983338" CI_START="0.7158369987705424" EFFECT_SIZE="0.8673076923076923" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="143" LOG_CI_END="0.021532254895844316" LOG_CI_START="-0.14518585840952145" LOG_EFFECT_SIZE="-0.06182680175683861" ORDER="86" O_E="0.0" SE="0.09793104502354248" STUDY_ID="STD-CONFIRM-2012" TOTAL_1="360" TOTAL_2="363" VAR="0.009590489579403106" WEIGHT="31.3774263707562" />
<DICH_DATA CI_END="0.893914006510788" CI_START="0.6709783578707409" EFFECT_SIZE="0.7744655913378355" ESTIMABLE="YES" EVENTS_1="301" EVENTS_2="190" LOG_CI_END="-0.0487042578194421" LOG_CI_START="-0.17329148759388957" LOG_EFFECT_SIZE="-0.11099787270666585" ORDER="78" O_E="0.0" SE="0.07318315548624409" STUDY_ID="STD-GALA-2013" TOTAL_1="943" TOTAL_2="461" VAR="0.005355774246923777" WEIGHT="37.21465670743481" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6592632417667589" CI_START="0.4738350727329709" DF="0" EFFECT_SIZE="0.5589114832535885" ESTIMABLE="YES" EVENTS_1="178" EVENTS_2="160" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="-0.18094113833622855" LOG_CI_START="-0.3243727964400649" LOG_EFFECT_SIZE="-0.25265696738814675" NO="4" P_CHI2="1.0" P_Z="5.01996953562599E-12" STUDIES="1" TAU2="0.0" TOTAL_1="627" TOTAL_2="315" WEIGHT="100.0" Z="6.905010554439566">
<NAME>Natalizumab versus placebo</NAME>
<DICH_DATA CI_END="0.6592632417667589" CI_START="0.4738350727329709" EFFECT_SIZE="0.5589114832535885" ESTIMABLE="YES" EVENTS_1="178" EVENTS_2="160" LOG_CI_END="-0.18094113833622855" LOG_CI_START="-0.3243727964400649" LOG_EFFECT_SIZE="-0.25265696738814675" ORDER="189" O_E="0.0" SE="0.08425246596835179" STUDY_ID="STD-AFFIRM-2006" TOTAL_1="627" TOTAL_2="315" VAR="0.007098478021748276" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7384471805383208" CI_START="0.21135400520957676" DF="0" EFFECT_SIZE="0.3950617283950617" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" I2="0.0" ID="CMP-001.01.05" LOG_CI_END="-0.13168056334610004" LOG_CI_START="-0.6749895177713875" LOG_EFFECT_SIZE="-0.4033350405587438" NO="5" P_CHI2="1.0" P_Z="0.003613963003191843" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="24" WEIGHT="100.0" Z="2.9100280669379157">
<NAME>Mitoxantrone versus placebo</NAME>
<DICH_DATA CI_END="0.7384471805383207" CI_START="0.21135400520957678" EFFECT_SIZE="0.3950617283950617" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" LOG_CI_END="-0.1316805633461001" LOG_CI_START="-0.6749895177713875" LOG_EFFECT_SIZE="-0.4033350405587438" ORDER="190" O_E="0.0" SE="0.3191423692521127" STUDY_ID="STD-Millefiorini-1997" TOTAL_1="27" TOTAL_2="24" VAR="0.10185185185185186" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.426021113364766" CI_END="0.8246220685384213" CI_START="0.48020004365473734" DF="1" EFFECT_SIZE="0.6292722410140223" ESTIMABLE="YES" EVENTS_1="422" EVENTS_2="328" I2="81.57028918415168" ID="CMP-001.01.06" LOG_CI_END="-0.08374504678882948" LOG_CI_START="-0.3185778047975032" LOG_EFFECT_SIZE="-0.2011614257931663" NO="6" P_CHI2="0.019838910666205245" P_Z="7.854502846688245E-4" STUDIES="2" TAU2="0.031043049090819817" TOTAL_1="1582" TOTAL_2="773" WEIGHT="100.0" Z="3.3578718146194073">
<NAME>Fingolimod versus placebo</NAME>
<DICH_DATA CI_END="0.6469519175085634" CI_START="0.4639508069761985" EFFECT_SIZE="0.5478629976580797" ESTIMABLE="YES" EVENTS_1="197" EVENTS_2="176" LOG_CI_END="-0.1891279955858252" LOG_CI_START="-0.33352806554722825" LOG_EFFECT_SIZE="-0.2613280305665267" ORDER="9" O_E="0.0" SE="0.0848213158872025" STUDY_ID="STD-FREEDOMS-2010" TOTAL_1="854" TOTAL_2="418" VAR="0.007194655628836592" WEIGHT="49.7623345149598" />
<DICH_DATA CI_END="0.8487840182833797" CI_START="0.6138674618805635" EFFECT_SIZE="0.7218316223250434" ESTIMABLE="YES" EVENTS_1="225" EVENTS_2="152" LOG_CI_END="-0.07120280634126201" LOG_CI_START="-0.21192538584144427" LOG_EFFECT_SIZE="-0.14156409609135315" ORDER="149" O_E="0.0" SE="0.08266113978641003" STUDY_ID="STD-FREEDOMS-II-2014" TOTAL_1="728" TOTAL_2="355" VAR="0.00683286403078842" WEIGHT="50.2376654850402" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.13785354771831543" CI_END="0.9457002630793014" CI_START="0.777301483376795" DF="1" EFFECT_SIZE="0.8573763568709871" ESTIMABLE="YES" EVENTS_1="604" EVENTS_2="352" I2="0.0" ID="CMP-001.01.07" LOG_CI_END="-0.024246490149635147" LOG_CI_START="-0.10941050350029949" LOG_EFFECT_SIZE="-0.06682849682496733" NO="7" P_CHI2="0.7104243766584712" P_Z="0.0020981115749064624" STUDIES="2" TAU2="0.0" TOTAL_1="1505" TOTAL_2="752" WEIGHT="100.00000000000001" Z="3.075981080848475">
<NAME>Teriflunomide versus placebo</NAME>
<DICH_DATA CI_END="1.0062932270829712" CI_START="0.7590725910589611" EFFECT_SIZE="0.873984901040604" ESTIMABLE="YES" EVENTS_1="295" EVENTS_2="169" LOG_CI_END="0.0027245496545612517" LOG_CI_START="-0.1197166899953446" LOG_EFFECT_SIZE="-0.0584960701703917" ORDER="30" O_E="0.0" SE="0.07192259026426592" STUDY_ID="STD-TEMSO-2011" TOTAL_1="725" TOTAL_2="363" VAR="0.00517285899032148" WEIGHT="48.378990602675046" />
<DICH_DATA CI_END="0.9652268163866307" CI_START="0.7346752297953841" EFFECT_SIZE="0.8420975199663724" ESTIMABLE="YES" EVENTS_1="309" EVENTS_2="183" LOG_CI_END="-0.015370620821523075" LOG_CI_START="-0.13390460251921196" LOG_EFFECT_SIZE="-0.07463761167036752" ORDER="98" O_E="0.0" SE="0.06962744760189488" STUDY_ID="STD-TOWER-2014" TOTAL_1="780" TOTAL_2="389" VAR="0.004847981459554616" WEIGHT="51.62100939732497" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.621746328537774" CI_END="0.8847055072814842" CI_START="0.7053926897328736" DF="1" EFFECT_SIZE="0.789977719560984" ESTIMABLE="YES" EVENTS_1="486" EVENTS_2="310" I2="0.0" ID="CMP-001.01.08" LOG_CI_END="-0.05320126924203056" LOG_CI_START="-0.15156904541296506" LOG_EFFECT_SIZE="-0.1023851573274978" NO="8" P_CHI2="0.43039928433153807" P_Z="4.503192913862965E-5" STUDIES="2" TAU2="0.0" TOTAL_1="1534" TOTAL_2="773" WEIGHT="100.0" Z="4.080019468258686">
<NAME>Dimethyl fumarate versus placebo</NAME>
<DICH_DATA CI_END="0.9789323528650083" CI_START="0.7027059414101582" EFFECT_SIZE="0.8293983244478293" ESTIMABLE="YES" EVENTS_1="231" EVENTS_2="143" LOG_CI_END="-0.009247318199416286" LOG_CI_START="-0.1532263744679925" LOG_EFFECT_SIZE="-0.08123684633370441" ORDER="15" O_E="0.0" SE="0.08457401035998463" STUDY_ID="STD-CONFIRM-2012" TOTAL_1="707" TOTAL_2="363" VAR="0.007152763228370789" WEIGHT="46.67744343945479" />
<DICH_DATA CI_END="0.8840089749030715" CI_START="0.6482573338148119" EFFECT_SIZE="0.7570107668580613" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="167" LOG_CI_END="-0.053543325788857295" LOG_CI_START="-0.18825256130402135" LOG_EFFECT_SIZE="-0.1208979435464393" ORDER="14" O_E="0.0" SE="0.07912887176307752" STUDY_ID="STD-DEFINE-2012" TOTAL_1="827" TOTAL_2="410" VAR="0.0062613783464975665" WEIGHT="53.322556560545216" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.007974343511584" CI_START="0.7846473565118957" DF="0" EFFECT_SIZE="0.8893280632411067" ESTIMABLE="YES" EVENTS_1="396" EVENTS_2="220" I2="0.0" ID="CMP-001.01.09" LOG_CI_END="0.0034494779297937826" LOG_CI_START="-0.1053254840587047" LOG_EFFECT_SIZE="-0.05093800306445545" NO="9" P_CHI2="1.0" P_Z="0.06640869720202656" STUDIES="1" TAU2="0.0" TOTAL_1="1012" TOTAL_2="500" WEIGHT="100.0" Z="1.8356550004821885">
<NAME>Pegylated interferon beta-1a versus placebo</NAME>
<DICH_DATA CI_END="1.007974343511584" CI_START="0.7846473565118957" EFFECT_SIZE="0.8893280632411067" ESTIMABLE="YES" EVENTS_1="396" EVENTS_2="220" LOG_CI_END="0.0034494779297937826" LOG_CI_START="-0.1053254840587047" LOG_EFFECT_SIZE="-0.05093800306445545" ORDER="103" O_E="0.0" SE="0.06389495111678976" STUDY_ID="STD-ADVANCE-2014" TOTAL_1="1012" TOTAL_2="500" VAR="0.004082564778216953" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9227265185605299" CI_START="0.6778852597895045" DF="0" EFFECT_SIZE="0.7908872901678657" ESTIMABLE="YES" EVENTS_1="194" EVENTS_2="120" I2="0.0" ID="CMP-001.01.10" LOG_CI_END="-0.034926997868252006" LOG_CI_START="-0.16884380946226302" LOG_EFFECT_SIZE="-0.10188540366525753" NO="10" P_CHI2="1.0" P_Z="0.002860682232335069" STUDIES="1" TAU2="0.0" TOTAL_1="417" TOTAL_2="204" WEIGHT="100.0" Z="2.982324912866436">
<NAME>Daclizumab versus placebo</NAME>
<DICH_DATA CI_END="0.9227265185605299" CI_START="0.6778852597895045" EFFECT_SIZE="0.7908872901678657" ESTIMABLE="YES" EVENTS_1="194" EVENTS_2="120" LOG_CI_END="-0.034926997868252006" LOG_CI_START="-0.16884380946226302" LOG_EFFECT_SIZE="-0.10188540366525753" ORDER="53" O_E="0.0" SE="0.07866339802923059" STUDY_ID="STD-SELECT-2013" TOTAL_1="417" TOTAL_2="204" VAR="0.006187930189505159" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.8002554349488437E-31" CI_END="1.2448268889556582" CI_START="0.61448762057806" DF="0" EFFECT_SIZE="0.8746031746031746" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" I2="100.0" ID="CMP-001.01.11" LOG_CI_END="0.09510896075016295" LOG_CI_START="-0.21148686195375618" LOG_EFFECT_SIZE="-0.05818895060179666" NO="11" P_CHI2="0.0" P_Z="0.45689778635588396" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="29" WEIGHT="100.0" Z="0.743964783811413">
<NAME>Azathioprine versus placebo</NAME>
<DICH_DATA CI_END="1.2448268889556582" CI_START="0.61448762057806" EFFECT_SIZE="0.8746031746031746" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" LOG_CI_END="0.09510896075016295" LOG_CI_START="-0.21148686195375618" LOG_EFFECT_SIZE="-0.05818895060179666" ORDER="193" O_E="0.0" SE="0.18009590393008124" STUDY_ID="STD-Goodkin-1991" TOTAL_1="30" TOTAL_2="29" VAR="0.032434534612393054" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.767267424454545" CI_END="1.358110931351206" CI_START="0.47302076722745307" DF="2" EFFECT_SIZE="0.8015077508843806" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="52" I2="83.00370062259627" ID="CMP-001.01.12" LOG_CI_END="0.13293524483850844" LOG_CI_START="-0.3251197918323789" LOG_EFFECT_SIZE="-0.09609227349693521" NO="12" P_CHI2="0.0027846655799881326" P_Z="0.41088614332430895" STUDIES="3" TAU2="0.18011422957373366" TOTAL_1="140" TOTAL_2="79" WEIGHT="100.0" Z="0.822335222489372">
<NAME>Immunoglobulins versus placebo</NAME>
<DICH_DATA CI_END="2.0428281506389356" CI_START="0.9032161441578856" EFFECT_SIZE="1.3583502366463827" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="17" LOG_CI_END="0.3102318339019845" LOG_CI_START="-0.044208308399271125" LOG_EFFECT_SIZE="0.1330117627513567" ORDER="604" O_E="0.0" SE="0.2081998940947583" STUDY_ID="STD-Fazekas-2008" TOTAL_1="87" TOTAL_2="41" VAR="0.04334719590106858" WEIGHT="32.39723640754555" />
<DICH_DATA CI_END="0.91591054186798" CI_START="0.43551411248687133" EFFECT_SIZE="0.631578947368421" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="-0.03814694234782351" LOG_CI_START="-0.3609977674625848" LOG_EFFECT_SIZE="-0.19957235490520417" ORDER="197" O_E="0.0" SE="0.18964417280976953" STUDY_ID="STD-Achiron-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.03596491228070173" WEIGHT="33.504078954327284" />
<DICH_DATA CI_END="0.8722612034421335" CI_START="0.43169360885353203" EFFECT_SIZE="0.6136363636363636" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="-0.05935344370633522" LOG_CI_START="-0.364824380948065" LOG_EFFECT_SIZE="-0.21208891232720012" ORDER="195" O_E="0.0" SE="0.17943514064131835" STUDY_ID="STD-Lewanska-2002" TOTAL_1="33" TOTAL_2="18" VAR="0.032196969696969696" WEIGHT="34.098684638127175" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0288247810874722" CI_START="0.7970170192750141" DF="0" EFFECT_SIZE="0.9055334672879882" ESTIMABLE="YES" EVENTS_1="188" EVENTS_2="207" I2="0.0" ID="CMP-001.01.13" LOG_CI_END="0.012341416466547704" LOG_CI_START="-0.09853240470387839" LOG_EFFECT_SIZE="-0.04309549411866534" NO="13" P_CHI2="1.0" P_Z="0.12759991896405692" STUDIES="1" TAU2="0.0" TOTAL_1="339" TOTAL_2="338" WEIGHT="100.0" Z="1.5236349839284091">
<NAME>Interferon beta-1a (Rebif) versus interferon beta-1a (Avonex)</NAME>
<DICH_DATA CI_END="1.0288247810874722" CI_START="0.7970170192750141" EFFECT_SIZE="0.9055334672879882" ESTIMABLE="YES" EVENTS_1="188" EVENTS_2="207" LOG_CI_END="0.012341416466547704" LOG_CI_START="-0.09853240470387839" LOG_EFFECT_SIZE="-0.04309549411866534" ORDER="201" O_E="0.0" SE="0.06512783138977461" STUDY_ID="STD-EVIDENCE-2007" TOTAL_1="339" TOTAL_2="338" VAR="0.004241634421534912" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.378461948799073" CI_START="0.4812443907568809" DF="0" EFFECT_SIZE="0.8144796380090498" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" I2="0.0" ID="CMP-001.01.14" LOG_CI_END="0.13939478229911928" LOG_CI_START="-0.3176343194627286" LOG_EFFECT_SIZE="-0.08911976858180463" NO="14" P_CHI2="1.0" P_Z="0.4446419137472969" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="36" WEIGHT="100.0" Z="0.7643781809846345">
<NAME>Glatiramer acetate versus interferon beta-1b (Betaseron)</NAME>
<DICH_DATA CI_END="1.378461948799073" CI_START="0.4812443907568809" EFFECT_SIZE="0.8144796380090498" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.13939478229911928" LOG_CI_START="-0.3176343194627286" LOG_EFFECT_SIZE="-0.08911976858180463" ORDER="79" O_E="0.0" SE="0.26846115670544957" STUDY_ID="STD-BECOME-2009" TOTAL_1="39" TOTAL_2="36" VAR="0.07207139265962796" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.3154575878658807" CI_END="1.3313341648556465" CI_START="0.49360827529732737" DF="1" EFFECT_SIZE="0.8106525525518337" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="52" I2="56.81199235777479" ID="CMP-001.01.15" LOG_CI_END="0.12428707706597732" LOG_CI_START="-0.30661756800674467" LOG_EFFECT_SIZE="-0.09116524547038365" NO="15" P_CHI2="0.1280937370536932" P_Z="0.40691895970320235" STUDIES="2" TAU2="0.07393451814641123" TOTAL_1="124" TOTAL_2="120" WEIGHT="100.0" Z="0.8293277865851277">
<NAME>Azathioprine versus interferons beta (Avonex, Rebif or Betaseron)</NAME>
<DICH_DATA CI_END="1.031244798630626" CI_START="0.3592846213308619" EFFECT_SIZE="0.6086956521739131" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="23" LOG_CI_END="0.01336177107874343" LOG_CI_START="-0.4445613717574531" LOG_EFFECT_SIZE="-0.21559980033935483" ORDER="176" O_E="0.0" SE="0.26898632085809665" STUDY_ID="STD-Etemadifar-2007" TOTAL_1="47" TOTAL_2="47" VAR="0.07235364080877493" WEIGHT="43.79538829118351" />
<DICH_DATA CI_END="1.5002150651746724" CI_START="0.684601961969883" EFFECT_SIZE="1.0134348410210479" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="29" LOG_CI_END="0.17615352233797318" LOG_CI_START="-0.16456186057139197" LOG_EFFECT_SIZE="0.005795830883290598" ORDER="178" O_E="0.0" SE="0.2001379024893071" STUDY_ID="STD-MAIN-TRIAL" TOTAL_1="77" TOTAL_2="73" VAR="0.040055180012819394" WEIGHT="56.20461170881649" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7935097005048573" CI_START="0.5684554065268794" DF="0" EFFECT_SIZE="0.6716210831886615" ESTIMABLE="YES" EVENTS_1="217" EVENTS_2="164" I2="0.0" ID="CMP-001.01.16" LOG_CI_END="-0.1004477597094099" LOG_CI_START="-0.24530359862604856" LOG_EFFECT_SIZE="-0.1728756791677292" NO="16" P_CHI2="1.0" P_Z="2.894468258894263E-6" STUDIES="1" TAU2="0.0" TOTAL_1="857" TOTAL_2="435" WEIGHT="100.0" Z="4.678169792888223">
<NAME>Fingolimod versus interferon beta-1a (Avonex)</NAME>
<DICH_DATA CI_END="0.7935097005048573" CI_START="0.5684554065268794" EFFECT_SIZE="0.6716210831886615" ESTIMABLE="YES" EVENTS_1="217" EVENTS_2="164" LOG_CI_END="-0.1004477597094099" LOG_CI_START="-0.24530359862604856" LOG_EFFECT_SIZE="-0.1728756791677292" ORDER="10" O_E="0.0" SE="0.08508903682760058" STUDY_ID="STD-TRASFORMS-2010" TOTAL_1="857" TOTAL_2="435" VAR="0.007240144188248768" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1794333565258226" CI_START="0.6947638509314181" DF="0" EFFECT_SIZE="0.9052224371373307" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="47" I2="0.0" ID="CMP-001.01.17" LOG_CI_END="0.07167340625529058" LOG_CI_START="-0.1581627862949275" LOG_EFFECT_SIZE="-0.043244690019818476" NO="17" P_CHI2="1.0" P_Z="0.46078693329457543" STUDIES="1" TAU2="0.0" TOTAL_1="220" TOTAL_2="104" WEIGHT="100.0" Z="0.7375516799245944">
<NAME>Teriflunomide versus interferon beta-1a (Rebif)</NAME>
<DICH_DATA CI_END="1.1794333565258226" CI_START="0.6947638509314181" EFFECT_SIZE="0.9052224371373307" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="47" LOG_CI_END="0.07167340625529058" LOG_CI_START="-0.1581627862949275" LOG_EFFECT_SIZE="-0.043244690019818476" ORDER="68" O_E="0.0" SE="0.13500691721149993" STUDY_ID="STD-TENERE-2014" TOTAL_1="220" TOTAL_2="104" VAR="0.018226867694952797" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1428342111376055" CI_START="0.8001965565838103" DF="0" EFFECT_SIZE="0.9562907510263221" ESTIMABLE="YES" EVENTS_1="231" EVENTS_2="123" I2="0.0" ID="CMP-001.01.18" LOG_CI_END="0.05798323266091031" LOG_CI_START="-0.09680332181464188" LOG_EFFECT_SIZE="-0.019410044576865782" NO="18" P_CHI2="1.0" P_Z="0.6230345491668796" STUDIES="1" TAU2="0.0" TOTAL_1="707" TOTAL_2="360" WEIGHT="100.0" Z="0.4915541719740603">
<NAME>Dimethyl fumarate versus glatiramer acetate</NAME>
<DICH_DATA CI_END="1.1428342111376055" CI_START="0.8001965565838103" EFFECT_SIZE="0.9562907510263221" ESTIMABLE="YES" EVENTS_1="231" EVENTS_2="123" LOG_CI_END="0.05798323266091031" LOG_CI_START="-0.09680332181464188" LOG_EFFECT_SIZE="-0.019410044576865782" ORDER="87" O_E="0.0" SE="0.09092238830474124" STUDY_ID="STD-CONFIRM-2012" TOTAL_1="707" TOTAL_2="360" VAR="0.008266880695038146" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.1941685545236527" CI_END="0.5478907958315645" CI_START="0.38927319895874246" DF="2" EFFECT_SIZE="0.46182161358408114" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="221" I2="8.849299846328629" ID="CMP-001.01.19" LOG_CI_END="-0.261305995336668" LOG_CI_START="-0.4097454959607573" LOG_EFFECT_SIZE="-0.3355257456487127" NO="19" P_CHI2="0.33384331766112907" P_Z="7.971145439367612E-19" STUDIES="3" TAU2="0.0023888347679129843" TOTAL_1="1045" TOTAL_2="537" WEIGHT="100.0" Z="8.860422927759474">
<NAME>Alemtuzumab versus interferon beta-1a (Rebif)</NAME>
<DICH_DATA CI_END="0.5369047999765317" CI_START="0.1920770816232309" EFFECT_SIZE="0.3211340951829886" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="31" LOG_CI_END="-0.2701027133882193" LOG_CI_START="-0.7165244514753702" LOG_EFFECT_SIZE="-0.49331358243179474" ORDER="73" O_E="0.0" SE="0.26223033877563556" STUDY_ID="STD-CAMMS223-2008" TOTAL_1="223" TOTAL_2="111" VAR="0.0687647505743846" WEIGHT="10.685070322510724" />
<DICH_DATA CI_END="0.647391809734742" CI_START="0.360193855926252" EFFECT_SIZE="0.4828939347759829" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="68" LOG_CI_END="-0.18883279923296195" LOG_CI_START="-0.44346369951227355" LOG_EFFECT_SIZE="-0.3161482493726177" ORDER="28" O_E="0.0" SE="0.14957145126735216" STUDY_ID="STD-CARE_x002d_MS-I-2012" TOTAL_1="386" TOTAL_2="195" VAR="0.022371619034221902" WEIGHT="30.705457547618337" />
<DICH_DATA CI_END="0.5897331091864965" CI_START="0.39402317533829545" EFFECT_SIZE="0.48204617235674535" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="122" LOG_CI_END="-0.2293444890895045" LOG_CI_START="-0.4044782334395606" LOG_EFFECT_SIZE="-0.3169113612645325" ORDER="33" O_E="0.0" SE="0.10287442835723908" STUDY_ID="STD-CARE_x002d_MS-II-2012" TOTAL_1="436" TOTAL_2="231" VAR="0.010583148009828715" WEIGHT="58.60947212987094" />
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="213.31550698472887" CI_END="0.8826934015527713" CI_START="0.8323077750321212" CI_STUDY="95" CI_TOTAL="95" DF="29" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8571304341125228" ESTIMABLE="YES" EVENTS_1="5504" EVENTS_2="5239" I2="86.40511399760726" I2_Q="86.3699756843136" ID="CMP-001.02" LOG_CI_END="-0.05419011990629638" LOG_CI_START="-0.07971604837104626" LOG_EFFECT_SIZE="-0.06695308413867133" METHOD="MH" NO="2" P_CHI2="-6.661338147750939E-16" P_Q="-4.440892098500626E-16" P_Z="8.516515079683875E-25" Q="139.39813722953863" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="26" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.028632647383752853" TOTALS="SUB" TOTAL_1="10704" TOTAL_2="8684" WEIGHT="2000.0" Z="10.281752042586202">
<NAME>Comparisons for relapses over 24 months</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9885813215230393" CI_START="0.8082165361948802" DF="0" EFFECT_SIZE="0.8938611589213998" ESTIMABLE="YES" EVENTS_1="190" EVENTS_2="105" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-0.004987599454959274" LOG_CI_START="-0.0924722680919358" LOG_EFFECT_SIZE="-0.048729933773447545" NO="1" P_CHI2="1.0" P_Z="0.029003166100848726" STUDIES="1" TAU2="0.0" TOTAL_1="249" TOTAL_2="123" WEIGHT="100.0" Z="2.1834434913687524">
<NAME>Interferon beta-1b (Betaseron) versus placebo</NAME>
<DICH_DATA CI_END="0.9885813215230393" CI_START="0.8082165361948802" EFFECT_SIZE="0.8938611589213998" ESTIMABLE="YES" EVENTS_1="190" EVENTS_2="105" LOG_CI_END="-0.004987599454959274" LOG_CI_START="-0.0924722680919358" LOG_EFFECT_SIZE="-0.048729933773447545" ORDER="277" O_E="0.0" SE="0.05138892741345401" STUDY_ID="STD-IFNB-MS-Group-1993" TOTAL_1="249" TOTAL_2="123" VAR="0.0026408218607052447" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.0835007957956972" CI_END="1.044117307425164" CI_START="0.7622753490339478" DF="1" EFFECT_SIZE="0.8921350149780596" ESTIMABLE="YES" EVENTS_1="309" EVENTS_2="343" I2="67.56932894703696" ID="CMP-001.02.02" LOG_CI_END="0.01874929474422941" LOG_CI_START="-0.11788812450601896" LOG_EFFECT_SIZE="-0.04956941488089478" NO="2" P_CHI2="0.07909037894232618" P_Z="0.155004739004666" STUDIES="2" TAU2="0.008789401736380311" TOTAL_1="605" TOTAL_2="593" WEIGHT="100.0" Z="1.422074105825164">
<NAME>Interferon beta-1a (Avonex) versus placebo</NAME>
<DICH_DATA CI_END="0.9552505765110221" CI_START="0.7144718562658633" EFFECT_SIZE="0.8261353718361574" ESTIMABLE="YES" EVENTS_1="183" EVENTS_2="223" LOG_CI_END="-0.01988269153488976" LOG_CI_START="-0.1460148738137582" LOG_EFFECT_SIZE="-0.08294878267432398" ORDER="140" O_E="0.0" SE="0.07409066823497923" STUDY_ID="STD-BRAVO-2014" TOTAL_1="447" TOTAL_2="450" VAR="0.005489427119505759" WEIGHT="45.11509924797556" />
<DICH_DATA CI_END="1.057018188717829" CI_START="0.8543858332868058" EFFECT_SIZE="0.9503164556962025" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="120" LOG_CI_END="0.024082460525800976" LOG_CI_START="-0.06834596136464646" LOG_EFFECT_SIZE="-0.02213175041942276" ORDER="279" O_E="0.0" SE="0.054292912546516074" STUDY_ID="STD-MSCRG-1996" TOTAL_1="158" TOTAL_2="143" VAR="0.0029477203527836426" WEIGHT="54.884900752024436" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9222783392750789" CI_START="0.774245838959568" DF="0" EFFECT_SIZE="0.8450267253443944" ESTIMABLE="YES" EVENTS_1="268" EVENTS_2="159" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="-0.035137991127783604" LOG_CI_START="-0.11112111999991904" LOG_EFFECT_SIZE="-0.07312955556385131" NO="3" P_CHI2="1.0" P_Z="1.6148156044619048E-4" STUDIES="1" TAU2="0.0" TOTAL_1="373" TOTAL_2="187" WEIGHT="100.0" Z="3.7727136862649466">
<NAME>Interferon beta-1a (Rebif) versus placebo</NAME>
<DICH_DATA CI_END="0.9222783392750789" CI_START="0.774245838959568" EFFECT_SIZE="0.8450267253443944" ESTIMABLE="YES" EVENTS_1="268" EVENTS_2="159" LOG_CI_END="-0.035137991127783604" LOG_CI_START="-0.11112111999991904" LOG_EFFECT_SIZE="-0.07312955556385131" ORDER="280" O_E="0.0" SE="0.04463286602204631" STUDY_ID="STD-PRISMS-1998" TOTAL_1="373" TOTAL_2="187" VAR="0.001992092729341936" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.44430516993419" CI_END="0.9847470725745153" CI_START="0.7495641652506209" DF="2" EFFECT_SIZE="0.8591455740660655" ESTIMABLE="YES" EVENTS_1="304" EVENTS_2="357" I2="41.933135964307894" ID="CMP-001.02.04" LOG_CI_END="-0.0066753015740365655" LOG_CI_START="-0.12519118413457844" LOG_EFFECT_SIZE="-0.06593324285430748" NO="4" P_CHI2="0.17868139954122852" P_Z="0.029201880231140034" STUDIES="3" TAU2="0.005959634858758906" TOTAL_1="510" TOTAL_2="514" WEIGHT="99.99999999999999" Z="2.1807504376025255">
<NAME>Glatiramer acetate versus placebo</NAME>
<DICH_DATA CI_END="0.948863619430372" CI_START="0.3532436575056798" EFFECT_SIZE="0.5789473684210527" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="-0.02279620441691449" LOG_CI_START="-0.45192562717229334" LOG_EFFECT_SIZE="-0.23736091579460392" ORDER="282" O_E="0.0" SE="0.25207274715141126" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="25" VAR="0.06354066985645931" WEIGHT="6.973352276448273" />
<DICH_DATA CI_END="0.9587594201206477" CI_START="0.7598447273194414" EFFECT_SIZE="0.8535269709543568" ESTIMABLE="YES" EVENTS_1="204" EVENTS_2="241" LOG_CI_END="-0.018290355938589336" LOG_CI_START="-0.1192751458216995" LOG_EFFECT_SIZE="-0.06878275088014439" ORDER="88" O_E="0.0" SE="0.05931896546011085" STUDY_ID="STD-CONFIRM-2012" TOTAL_1="360" TOTAL_2="363" VAR="0.0035187396632578236" WEIGHT="51.13219645140123" />
<DICH_DATA CI_END="1.0710913219251927" CI_START="0.7986033144958462" EFFECT_SIZE="0.9248659793814433" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="97" LOG_CI_END="0.02982650063334549" LOG_CI_START="-0.09766889165699663" LOG_EFFECT_SIZE="-0.03392119551182557" ORDER="281" O_E="0.0" SE="0.07489142454371729" STUDY_ID="STD-Johnson-1995" TOTAL_1="125" TOTAL_2="126" VAR="0.005608725470187301" WEIGHT="41.894451272150484" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6360150609565594" CI_START="0.4875190452556713" DF="0" EFFECT_SIZE="0.556838805477644" ESTIMABLE="YES" EVENTS_1="225" EVENTS_2="203" I2="0.0" ID="CMP-001.02.05" LOG_CI_END="-0.19653260005460413" LOG_CI_START="-0.3120084136313286" LOG_EFFECT_SIZE="-0.25427050684296637" NO="5" P_CHI2="1.0" P_Z="6.058656556254218E-18" STUDIES="1" TAU2="0.0" TOTAL_1="627" TOTAL_2="315" WEIGHT="100.0" Z="8.631435801261333">
<NAME>Natalizumab versus placebo</NAME>
<DICH_DATA CI_END="0.6360150609565594" CI_START="0.4875190452556713" EFFECT_SIZE="0.556838805477644" ESTIMABLE="YES" EVENTS_1="225" EVENTS_2="203" LOG_CI_END="-0.19653260005460413" LOG_CI_START="-0.3120084136313286" LOG_EFFECT_SIZE="-0.25427050684296637" ORDER="283" O_E="0.0" SE="0.06783106450946402" STUDY_ID="STD-AFFIRM-2006" TOTAL_1="627" TOTAL_2="315" VAR="0.004601053312487069" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6672941841561428E-31" CI_END="0.7971368034909756" CI_START="0.2745711434916223" DF="0" EFFECT_SIZE="0.46783625730994155" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" I2="100.00000000000001" ID="CMP-001.02.06" LOG_CI_END="-0.09846713920268753" LOG_CI_START="-0.561345107597733" LOG_EFFECT_SIZE="-0.32990612340021025" NO="6" P_CHI2="0.0" P_Z="0.005208580513968199" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="24" WEIGHT="100.0" Z="2.7938427157621444">
<NAME>Mitoxantrone versus placebo</NAME>
<DICH_DATA CI_END="0.7971368034909755" CI_START="0.2745711434916223" EFFECT_SIZE="0.4678362573099415" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" LOG_CI_END="-0.09846713920268758" LOG_CI_START="-0.561345107597733" LOG_EFFECT_SIZE="-0.32990612340021025" ORDER="285" O_E="0.0" SE="0.2718968099181466" STUDY_ID="STD-Millefiorini-1997" TOTAL_1="27" TOTAL_2="24" VAR="0.07392787524366473" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.20115169890413984" CI_END="0.7786707889671376" CI_START="0.6663793049881416" DF="1" EFFECT_SIZE="0.7203402662398438" ESTIMABLE="YES" EVENTS_1="704" EVENTS_2="477" I2="0.0" ID="CMP-001.02.07" LOG_CI_END="-0.10864611710857067" LOG_CI_START="-0.17627849879966712" LOG_EFFECT_SIZE="-0.14246230795411888" NO="7" P_CHI2="0.6537928398837842" P_Z="1.4935334837026387E-16" STUDIES="2" TAU2="0.0" TOTAL_1="1582" TOTAL_2="773" WEIGHT="100.0" Z="8.257020846015406">
<NAME>Fingolimod versus placebo</NAME>
<DICH_DATA CI_END="0.7849855252466786" CI_START="0.6421555661035376" EFFECT_SIZE="0.7099879043672954" ESTIMABLE="YES" EVENTS_1="396" EVENTS_2="273" LOG_CI_END="-0.10513835136105604" LOG_CI_START="-0.19235974869737127" LOG_EFFECT_SIZE="-0.14874905002921363" ORDER="11" O_E="0.0" SE="0.0512342805482316" STUDY_ID="STD-FREEDOMS-2010" TOTAL_1="854" TOTAL_2="418" VAR="0.002624951503294903" WEIGHT="60.12613434400844" />
<DICH_DATA CI_END="0.832856380445257" CI_START="0.6508260511109203" EFFECT_SIZE="0.736236802413273" ESTIMABLE="YES" EVENTS_1="308" EVENTS_2="204" LOG_CI_END="-0.07942988281613221" LOG_CI_START="-0.18653507155066287" LOG_EFFECT_SIZE="-0.13298247718339756" ORDER="150" O_E="0.0" SE="0.06291411804189816" STUDY_ID="STD-FREEDOMS-II-2014" TOTAL_1="728" TOTAL_2="355" VAR="0.003958186248989895" WEIGHT="39.873865655991565" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9804887531262183" CI_START="0.7911725100831253" DF="0" EFFECT_SIZE="0.8807586206896552" ESTIMABLE="YES" EVENTS_1="387" EVENTS_2="220" I2="0.0" ID="CMP-001.02.08" LOG_CI_END="-0.00855738362111909" LOG_CI_START="-0.10172881105523293" LOG_EFFECT_SIZE="-0.05514309733817602" NO="8" P_CHI2="1.0" P_Z="0.02034130820518461" STUDIES="1" TAU2="0.0" TOTAL_1="725" TOTAL_2="363" WEIGHT="100.0" Z="2.3199920352243013">
<NAME>Teriflunomide versus placebo</NAME>
<DICH_DATA CI_END="0.9804887531262183" CI_START="0.7911725100831253" EFFECT_SIZE="0.8807586206896552" ESTIMABLE="YES" EVENTS_1="387" EVENTS_2="220" LOG_CI_END="-0.00855738362111909" LOG_CI_START="-0.10172881105523293" LOG_EFFECT_SIZE="-0.05514309733817602" ORDER="33" O_E="0.0" SE="0.0547293576808025" STUDY_ID="STD-TEMSO-2011" TOTAL_1="725" TOTAL_2="363" VAR="0.0029953025921532154" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9780395011064105" CI_END="0.9683537407047859" CI_START="0.8140909535946761" DF="1" EFFECT_SIZE="0.887878381416808" ESTIMABLE="YES" EVENTS_1="944" EVENTS_2="536" I2="49.44489230671819" ID="CMP-001.02.09" LOG_CI_END="-0.013965965447265456" LOG_CI_START="-0.089327071231674" LOG_EFFECT_SIZE="-0.05164651833946975" NO="9" P_CHI2="0.15959741963648455" P_Z="0.0072224966335121404" STUDIES="2" TAU2="0.00194750251630316" TOTAL_1="1534" TOTAL_2="773" WEIGHT="100.0" Z="2.6864073932734307">
<NAME>Dimethyl fumarate versus placebo</NAME>
<DICH_DATA CI_END="1.0220989081594507" CI_START="0.848028185458768" EFFECT_SIZE="0.931004125901624" ESTIMABLE="YES" EVENTS_1="437" EVENTS_2="241" LOG_CI_END="0.00949292435976473" LOG_CI_START="-0.07158971309023154" LOG_EFFECT_SIZE="-0.031048394365233427" ORDER="16" O_E="0.0" SE="0.04762834260365632" STUDY_ID="STD-CONFIRM-2012" TOTAL_1="707" TOTAL_2="363" VAR="0.002268459019171264" WEIGHT="46.48074589230738" />
<DICH_DATA CI_END="0.9240691573697872" CI_START="0.7856409389158907" EFFECT_SIZE="0.8520484495726846" ESTIMABLE="YES" EVENTS_1="507" EVENTS_2="295" LOG_CI_END="-0.03429552494855584" LOG_CI_START="-0.10477589400672059" LOG_EFFECT_SIZE="-0.06953570947763822" ORDER="17" O_E="0.0" SE="0.04140051766821952" STUDY_ID="STD-DEFINE-2012" TOTAL_1="827" TOTAL_2="410" VAR="0.0017140028631965564" WEIGHT="53.51925410769261" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.943363423560564" CI_END="0.9911400045266335" CI_START="0.7500964993010133" DF="1" EFFECT_SIZE="0.862235842280184" ESTIMABLE="YES" EVENTS_1="518" EVENTS_2="618" I2="66.02526239215449" ID="CMP-001.02.10" LOG_CI_END="-0.0038649944564536315" LOG_CI_START="-0.1248828613842528" LOG_EFFECT_SIZE="-0.06437392792035318" NO="10" P_CHI2="0.08623116650270546" P_Z="0.037055120500158" STUDIES="2" TAU2="0.006804236513236993" TOTAL_1="984" TOTAL_2="1006" WEIGHT="100.00000000000001" Z="2.085156241310132">
<NAME>Laquinimod versus placebo</NAME>
<DICH_DATA CI_END="0.88694503141741" CI_START="0.7420818884867695" EFFECT_SIZE="0.8112865362485616" ESTIMABLE="YES" EVENTS_1="317" EVENTS_2="395" LOG_CI_END="-0.05210329481521219" LOG_CI_START="-0.12954816782657796" LOG_EFFECT_SIZE="-0.09082573132089508" ORDER="76" O_E="0.0" SE="0.0454915017651804" STUDY_ID="STD-ALLEGRO-2012" TOTAL_1="550" TOTAL_2="556" VAR="0.0020694767328514117" WEIGHT="56.946731324967004" />
<DICH_DATA CI_END="1.0725035827425027" CI_START="0.8143839494293802" EFFECT_SIZE="0.9345746109813808" ESTIMABLE="YES" EVENTS_1="201" EVENTS_2="223" LOG_CI_END="0.030398751637834218" LOG_CI_START="-0.08917079436751185" LOG_EFFECT_SIZE="-0.029386021364838828" ORDER="139" O_E="0.0" SE="0.0702357432023387" STUDY_ID="STD-BRAVO-2014" TOTAL_1="434" TOTAL_2="450" VAR="0.004933059623184868" WEIGHT="43.05326867503301" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0527809272419684" CI_START="0.5562886465798307" DF="0" EFFECT_SIZE="0.7652777777777777" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="24" I2="0.0" ID="CMP-001.02.11" LOG_CI_END="0.022338008423566817" LOG_CI_START="-0.2546998035825337" LOG_EFFECT_SIZE="-0.11618089757948344" NO="11" P_CHI2="1.0" P_Z="0.10019813482658098" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="29" WEIGHT="100.0" Z="1.6438938302206203">
<NAME>Azathioprine versus placebo</NAME>
<DICH_DATA CI_END="1.0527809272419684" CI_START="0.5562886465798307" EFFECT_SIZE="0.7652777777777777" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="24" LOG_CI_END="0.022338008423566817" LOG_CI_START="-0.2546998035825337" LOG_EFFECT_SIZE="-0.11618089757948344" ORDER="289" O_E="0.0" SE="0.16273338213166985" STUDY_ID="STD-Goodkin-1991" TOTAL_1="30" TOTAL_2="29" VAR="0.026482153660012088" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.10071230410481305" CI_END="0.8965303102847452" CI_START="0.6060219665557471" DF="1" EFFECT_SIZE="0.7371004420807218" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="69" I2="0.0" ID="CMP-001.02.12" LOG_CI_END="-0.047435023037785996" LOG_CI_START="-0.21751163362076437" LOG_EFFECT_SIZE="-0.13247332832927516" NO="12" P_CHI2="0.7509765364550588" P_Z="0.0022637950436684845" STUDIES="2" TAU2="0.0" TOTAL_1="95" TOTAL_2="95" WEIGHT="100.0" Z="3.0532470225922372">
<NAME>Immunoglobulins versus placebo</NAME>
<DICH_DATA CI_END="0.9839295456736161" CI_START="0.5810207897780739" EFFECT_SIZE="0.7560975609756098" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="20" LOG_CI_END="-0.007035998134340997" LOG_CI_START="-0.23580832763658466" LOG_EFFECT_SIZE="-0.12142216288546281" ORDER="291" O_E="0.0" SE="0.13438199879091275" STUDY_ID="STD-Achiron-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.01805852159904088" WEIGHT="55.26907494219713" />
<DICH_DATA CI_END="0.9572387991193156" CI_START="0.5329956141581954" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="49" LOG_CI_END="-0.018979706734397313" LOG_CI_START="-0.2732763646220787" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="547" O_E="0.0" SE="0.14937511563198208" STUDY_ID="STD-Fazekas-1997" TOTAL_1="75" TOTAL_2="75" VAR="0.02231292517006802" WEIGHT="44.73092505780287" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7055355951666402" CI_START="1.0553462286776683" DF="0" EFFECT_SIZE="1.3416149068322982" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="49" I2="0.0" ID="CMP-001.02.13" LOG_CI_END="0.23186078772649302" LOG_CI_START="0.02339496251166937" LOG_EFFECT_SIZE="0.12762787511908122" NO="13" P_CHI2="1.0" P_Z="0.01640063800370449" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="96" WEIGHT="100.0" Z="2.399875743652465">
<NAME>Interferon beta-1a (Avonex) versus interferon beta-1b (Betaseron)</NAME>
<DICH_DATA CI_END="1.7055355951666402" CI_START="1.0553462286776683" EFFECT_SIZE="1.3416149068322982" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="49" LOG_CI_END="0.23186078772649302" LOG_CI_START="0.02339496251166937" LOG_EFFECT_SIZE="0.12762787511908122" ORDER="298" O_E="0.0" SE="0.12245385765366487" STUDY_ID="STD-INCOMIN-2002" TOTAL_1="92" TOTAL_2="96" VAR="0.01499494725426402" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.105446839135558" CI_START="0.8945183532827345" DF="0" EFFECT_SIZE="0.9944055944055944" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="130" I2="0.0" ID="CMP-001.02.14" LOG_CI_END="0.043537862224358334" LOG_CI_START="-0.04841074436698703" LOG_EFFECT_SIZE="-0.0024364410713143166" NO="14" P_CHI2="1.0" P_Z="0.9172727588011858" STUDIES="1" TAU2="0.0" TOTAL_1="143" TOTAL_2="158" WEIGHT="100.0" Z="0.1038696925871571">
<NAME>Interferon beta-1a (Rebif) versus interferon beta-1b (Betaseron)</NAME>
<DICH_DATA CI_END="1.105446839135558" CI_START="0.8945183532827345" EFFECT_SIZE="0.9944055944055944" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="130" LOG_CI_END="0.043537862224358334" LOG_CI_START="-0.04841074436698703" LOG_EFFECT_SIZE="-0.0024364410713143166" ORDER="550" O_E="0.0" SE="0.05401106666469952" STUDY_ID="STD-Koch_x002d_Henriksen-2006" TOTAL_1="143" TOTAL_2="158" VAR="0.0029171953222586157" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.535287394690985" CI_END="1.3772019649647576" CI_START="0.4652872862591706" DF="1" EFFECT_SIZE="0.8004964490297565" ESTIMABLE="YES" EVENTS_1="273" EVENTS_2="1047" I2="81.93409070396017" ID="CMP-001.02.15" LOG_CI_END="0.1389976336759285" LOG_CI_START="-0.3322788141826623" LOG_EFFECT_SIZE="-0.09664059025336685" NO="15" P_CHI2="0.018636807638406916" P_Z="0.4214976130754978" STUDIES="2" TAU2="0.12920825228458993" TOTAL_1="487" TOTAL_2="1832" WEIGHT="100.0" Z="0.8038257680898404">
<NAME>Glatiramer acetate versus interferon beta-1b (Betaseron)</NAME>
<DICH_DATA CI_END="0.9132447811769671" CI_START="0.36445895289698155" EFFECT_SIZE="0.5769230769230769" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="24" LOG_CI_END="-0.039412800925540725" LOG_CI_START="-0.4383513769047328" LOG_EFFECT_SIZE="-0.23888208891513676" ORDER="80" O_E="0.0" SE="0.23433849430797735" STUDY_ID="STD-BECOME-2009" TOTAL_1="39" TOTAL_2="36" VAR="0.05491452991452993" WEIGHT="41.62163611601062" />
<DICH_DATA CI_END="1.1052199368846918" CI_START="0.9249027499049527" EFFECT_SIZE="1.0110494344365313" ESTIMABLE="YES" EVENTS_1="258" EVENTS_2="1023" LOG_CI_END="0.04344871048344684" LOG_CI_START="-0.03390392931502369" LOG_EFFECT_SIZE="0.0047723905842115945" ORDER="302" O_E="0.0" SE="0.04543732351936395" STUDY_ID="STD-BEYOND-2009" TOTAL_1="448" TOTAL_2="1796" VAR="0.0020645503686033445" WEIGHT="58.37836388398939" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0922758963569368" CI_START="0.781496922415393" DF="0" EFFECT_SIZE="0.9239103048626858" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="168" I2="0.0" ID="CMP-001.02.16" LOG_CI_END="0.038332350027609055" LOG_CI_START="-0.1070727279207305" LOG_EFFECT_SIZE="-0.03437018894656071" NO="16" P_CHI2="1.0" P_Z="0.35414741215328616" STUDIES="1" TAU2="0.0" TOTAL_1="378" TOTAL_2="386" WEIGHT="100.0" Z="0.9265746895170922">
<NAME>Glatiramer acetate versus interferon beta-1a (Rebif)</NAME>
<DICH_DATA CI_END="1.0922758963569368" CI_START="0.781496922415393" EFFECT_SIZE="0.9239103048626858" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="168" LOG_CI_END="0.038332350027609055" LOG_CI_START="-0.1070727279207305" LOG_EFFECT_SIZE="-0.03437018894656071" ORDER="303" O_E="0.0" SE="0.08541166255359876" STUDY_ID="STD-REGARD-2008" TOTAL_1="378" TOTAL_2="386" VAR="0.007295152100169825" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.214343927388972" CI_START="0.9797764751796093" DF="0" EFFECT_SIZE="1.0907729428405026" ESTIMABLE="YES" EVENTS_1="437" EVENTS_2="204" I2="0.0" ID="CMP-001.02.17" LOG_CI_END="0.08434170536647685" LOG_CI_START="-0.00887299233665489" LOG_EFFECT_SIZE="0.037734356514910986" NO="17" P_CHI2="1.0" P_Z="0.11255095605966181" STUDIES="1" TAU2="0.0" TOTAL_1="707" TOTAL_2="360" WEIGHT="100.0" Z="1.5868308661915045">
<NAME>Dimethyl fumarate versus glatiramer acetate</NAME>
<DICH_DATA CI_END="1.214343927388972" CI_START="0.9797764751796093" EFFECT_SIZE="1.0907729428405026" ESTIMABLE="YES" EVENTS_1="437" EVENTS_2="204" LOG_CI_END="0.08434170536647685" LOG_CI_START="-0.00887299233665489" LOG_EFFECT_SIZE="0.037734356514910986" ORDER="89" O_E="0.0" SE="0.0547547748510149" STUDY_ID="STD-CONFIRM-2012" TOTAL_1="707" TOTAL_2="360" VAR="0.0029980853689853333" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.86869723785439" CI_END="0.6528975930524961" CI_START="0.3865205569343786" DF="2" EFFECT_SIZE="0.5023528055936047" ESTIMABLE="YES" EVENTS_1="295" EVENTS_2="286" I2="70.88239689794872" ID="CMP-001.02.18" LOG_CI_END="-0.18515493244615092" LOG_CI_START="-0.41282740336078805" LOG_EFFECT_SIZE="-0.29899116790346947" NO="18" P_CHI2="0.03224643518889592" P_Z="2.6348836431137125E-7" STUDIES="3" TAU2="0.03601900863222331" TOTAL_1="1045" TOTAL_2="537" WEIGHT="100.0" Z="5.147850492702616">
<NAME>Alemtuzumab versus interferon beta-1a (Rebif)</NAME>
<DICH_DATA CI_END="0.5014243664010978" CI_START="0.2087649137325136" EFFECT_SIZE="0.323542600896861" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="40" LOG_CI_END="-0.2997945655983469" LOG_CI_START="-0.6803424896389484" LOG_EFFECT_SIZE="-0.49006852761864766" ORDER="74" O_E="0.0" SE="0.22353573432405394" STUDY_ID="STD-CAMMS223-2008" TOTAL_1="223" TOTAL_2="111" VAR="0.049968224519794026" WEIGHT="20.79994905338921" />
<DICH_DATA CI_END="0.6653999801377593" CI_START="0.42542843272540964" EFFECT_SIZE="0.5320526954029324" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="94" LOG_CI_END="-0.1769172164309199" LOG_CI_START="-0.3711734881918514" LOG_EFFECT_SIZE="-0.27404535231138566" ORDER="29" O_E="0.0" SE="0.11410709561642461" STUDY_ID="STD-CARE_x002d_MS-I-2012" TOTAL_1="386" TOTAL_2="195" VAR="0.013020429270015867" WEIGHT="36.47125956805053" />
<DICH_DATA CI_END="0.6882915129757873" CI_START="0.5101398306092996" EFFECT_SIZE="0.5925579430226944" ESTIMABLE="YES" EVENTS_1="170" EVENTS_2="152" LOG_CI_END="-0.1622275855102035" LOG_CI_START="-0.2923107663756772" LOG_EFFECT_SIZE="-0.22726917594294033" ORDER="34" O_E="0.0" SE="0.07641150436250956" STUDY_ID="STD-CARE_x002d_MS-II-2012" TOTAL_1="436" TOTAL_2="231" VAR="0.0058387179989418175" WEIGHT="42.72879137856026" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.315029484983668" CI_START="0.9731729572062816" DF="0" EFFECT_SIZE="1.1312608597114149" ESTIMABLE="YES" EVENTS_1="201" EVENTS_2="183" I2="0.0" ID="CMP-001.02.19" LOG_CI_END="0.11893549048520569" LOG_CI_START="-0.011809967866235387" LOG_EFFECT_SIZE="0.05356276130948513" NO="19" P_CHI2="1.0" P_Z="0.1082991869851823" STUDIES="1" TAU2="0.0" TOTAL_1="434" TOTAL_2="447" WEIGHT="100.0" Z="1.6058849676738969">
<NAME>Laquinimod versus interferon beta-1a (Avonex)</NAME>
<DICH_DATA CI_END="1.3150294849836677" CI_START="0.9731729572062816" EFFECT_SIZE="1.1312608597114149" ESTIMABLE="YES" EVENTS_1="201" EVENTS_2="183" LOG_CI_END="0.1189354904852056" LOG_CI_START="-0.011809967866235387" LOG_EFFECT_SIZE="0.05356276130948513" ORDER="141" O_E="0.0" SE="0.07680052943609321" STUDY_ID="STD-BRAVO-2014" TOTAL_1="434" TOTAL_2="447" VAR="0.00589832132166422" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1579386886433656" CI_START="0.6354001568020491" DF="0" EFFECT_SIZE="0.8577612863327149" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="42" I2="0.0" ID="CMP-001.02.20" LOG_CI_END="0.06368556466880136" LOG_CI_START="-0.196952682335034" LOG_EFFECT_SIZE="-0.0666335588331163" NO="20" P_CHI2="1.0" P_Z="0.31627092169774784" STUDIES="1" TAU2="0.0" TOTAL_1="77" TOTAL_2="73" WEIGHT="100.0" Z="1.002150505353245">
<NAME>Azathioprine versus interferons beta (Avonex, Rebif or Betaseron)</NAME>
<DICH_DATA CI_END="1.1579386886433656" CI_START="0.6354001568020491" EFFECT_SIZE="0.8577612863327149" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="42" LOG_CI_END="0.06368556466880136" LOG_CI_START="-0.196952682335034" LOG_EFFECT_SIZE="-0.0666335588331163" ORDER="179" O_E="0.0" SE="0.1531001964701833" STUDY_ID="STD-MAIN-TRIAL" TOTAL_1="77" TOTAL_2="73" VAR="0.023439670159208725" WEIGHT="100.0" />
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="106.81579560085312" CI_END="0.8867564891850027" CI_START="0.8100113419764648" CI_STUDY="95" CI_TOTAL="95" DF="29" EFFECT_MEASURE="RR" EFFECT_SIZE="0.847515671720047" ESTIMABLE="YES" EVENTS_1="3118" EVENTS_2="3056" I2="72.85045733463753" I2_Q="74.00298978355598" ID="CMP-001.03" LOG_CI_END="-0.05219562472585104" LOG_CI_START="-0.0915088999814656" LOG_EFFECT_SIZE="-0.07185226235365832" METHOD="MH" NO="3" P_CHI2="7.718836680936647E-11" P_Q="2.8028494858389763E-8" P_Z="7.813285348055408E-13" Q="73.08532728114184" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="26" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.037761895468731314" TOTALS="SUB" TOTAL_1="10704" TOTAL_2="8684" WEIGHT="2000.0" Z="7.164391443105778">
<NAME>Comparisons for disability worsening over 24 months</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3201016178322402" CI_START="0.7218746139936101" DF="0" EFFECT_SIZE="0.9761904761904762" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="42" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.12060736330068184" LOG_CI_START="-0.1415382306570118" LOG_EFFECT_SIZE="-0.01046543367816498" NO="1" P_CHI2="1.0" P_Z="0.8756450506176358" STUDIES="1" TAU2="0.0" TOTAL_1="249" TOTAL_2="123" WEIGHT="100.0" Z="0.15649222084660497">
<NAME>Interferon beta-1b (Betaseron) versus placebo</NAME>
<DICH_DATA CI_END="1.3201016178322402" CI_START="0.7218746139936101" EFFECT_SIZE="0.9761904761904762" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="42" LOG_CI_END="0.12060736330068184" LOG_CI_START="-0.1415382306570118" LOG_EFFECT_SIZE="-0.01046543367816498" ORDER="539" O_E="0.0" SE="0.15398561953236742" STUDY_ID="STD-IFNB-MS-Group-1993" TOTAL_1="249" TOTAL_2="123" VAR="0.023711571022767018" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.3470393722629215" CI_END="1.086341776399018" CI_START="0.7044408369168367" DF="1" EFFECT_SIZE="0.874793409979892" ESTIMABLE="YES" EVENTS_1="203" EVENTS_2="229" I2="57.393130604543714" ID="CMP-001.03.02" LOG_CI_END="0.035966481102267286" LOG_CI_START="-0.15215547562700948" LOG_EFFECT_SIZE="-0.05809449726237107" NO="2" P_CHI2="0.12552135186981284" P_Z="0.22607770338452704" STUDIES="2" TAU2="0.014039688352032493" TOTAL_1="605" TOTAL_2="593" WEIGHT="100.0" Z="1.2105245375271823">
<NAME>Interferon beta-1a (Avonex) versus placebo</NAME>
<DICH_DATA CI_END="0.9653802260874309" CI_START="0.6350715294159913" EFFECT_SIZE="0.7829977628635347" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="144" LOG_CI_END="-0.015301601093321087" LOG_CI_START="-0.19717735647000048" LOG_EFFECT_SIZE="-0.1062394787816608" ORDER="140" O_E="0.0" SE="0.10683471900777043" STUDY_ID="STD-BRAVO-2014" TOTAL_1="447" TOTAL_2="450" VAR="0.011413657185469266" WEIGHT="47.974372787807106" />
<DICH_DATA CI_END="1.172106434784834" CI_START="0.8010060273381989" EFFECT_SIZE="0.9689501116902457" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="85" LOG_CI_END="0.06896705019824313" LOG_CI_START="-0.09636421596336303" LOG_EFFECT_SIZE="-0.013698582882559956" ORDER="540" O_E="0.0" SE="0.097116404146294" STUDY_ID="STD-MSCRG-1996" TOTAL_1="158" TOTAL_2="143" VAR="0.009431595954306309" WEIGHT="52.025627212192894" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.17585322129331E-31" CI_END="0.9642266385984053" CI_START="0.6121656943994401" DF="0" EFFECT_SIZE="0.7682880122558406" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="77" I2="100.0" ID="CMP-001.03.03" LOG_CI_END="-0.01582087447458018" LOG_CI_START="-0.21313101180251007" LOG_EFFECT_SIZE="-0.11447594313854514" NO="3" P_CHI2="0.0" P_Z="0.02294947597486995" STUDIES="1" TAU2="0.0" TOTAL_1="373" TOTAL_2="187" WEIGHT="100.0" Z="2.274274689443881">
<NAME>Interferon beta-1a (Rebif) versus placebo</NAME>
<DICH_DATA CI_END="0.9642266385984053" CI_START="0.6121656943994401" EFFECT_SIZE="0.7682880122558406" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="77" LOG_CI_END="-0.01582087447458018" LOG_CI_START="-0.21313101180251007" LOG_EFFECT_SIZE="-0.11447594313854514" ORDER="541" O_E="0.0" SE="0.11590095136735783" STUDY_ID="STD-PRISMS-1998" TOTAL_1="373" TOTAL_2="187" VAR="0.013433030527858644" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.7195365191748193" CI_END="1.0879929311709904" CI_START="0.6056826530655004" DF="2" EFFECT_SIZE="0.8117748733904961" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="192" I2="46.229859830931275" ID="CMP-001.03.04" LOG_CI_END="0.036626073704619455" LOG_CI_START="-0.21775486448398818" LOG_EFFECT_SIZE="-0.09056439538968429" NO="4" P_CHI2="0.1557088018619065" P_Z="0.1628446132784983" STUDIES="3" TAU2="0.03066159247511728" TOTAL_1="510" TOTAL_2="514" WEIGHT="99.99999999999999" Z="1.3955680367356709">
<NAME>Glatiramer acetate versus placebo</NAME>
<DICH_DATA CI_END="0.9178167568396305" CI_START="0.16117486740186832" EFFECT_SIZE="0.38461538461538464" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="-0.03724401753201925" LOG_CI_START="-0.7927026784096166" LOG_EFFECT_SIZE="-0.4149733479708179" ORDER="543" O_E="0.0" SE="0.4437601569801833" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="25" VAR="0.19692307692307692" WEIGHT="9.81073013745771" />
<DICH_DATA CI_END="1.0171743329174745" CI_START="0.6757581252864258" EFFECT_SIZE="0.8290740740740741" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="135" LOG_CI_END="0.007395392780758189" LOG_CI_START="-0.17020872365980505" LOG_EFFECT_SIZE="-0.08140666543952343" ORDER="90" O_E="0.0" SE="0.1043255371517421" STUDY_ID="STD-CONFIRM-2012" TOTAL_1="360" TOTAL_2="363" VAR="0.010883817701999522" WEIGHT="53.74292287329549" />
<DICH_DATA CI_END="1.3556803641613122" CI_START="0.6828998012465932" EFFECT_SIZE="0.9621818181818181" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="44" LOG_CI_END="0.13215730572251153" LOG_CI_START="-0.1656430136800726" LOG_EFFECT_SIZE="-0.016742853978780503" ORDER="542" O_E="0.0" SE="0.17492938175243347" STUDY_ID="STD-Johnson-1995" TOTAL_1="125" TOTAL_2="126" VAR="0.0306002886002886" WEIGHT="36.446346989246784" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7964152117591862" CI_START="0.5195412779322048" DF="0" EFFECT_SIZE="0.6432500111791799" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="107" I2="0.0" ID="CMP-001.03.05" LOG_CI_END="-0.09886045341612193" LOG_CI_START="-0.2843799417237156" LOG_EFFECT_SIZE="-0.1916201975699188" NO="5" P_CHI2="1.0" P_Z="5.1473721110603494E-5" STUDIES="1" TAU2="0.0" TOTAL_1="627" TOTAL_2="315" WEIGHT="100.0" Z="4.048832706187641">
<NAME>Natalizumab versus placebo</NAME>
<DICH_DATA CI_END="0.7964152117591862" CI_START="0.5195412779322048" EFFECT_SIZE="0.6432500111791799" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="107" LOG_CI_END="-0.09886045341612193" LOG_CI_START="-0.2843799417237156" LOG_EFFECT_SIZE="-0.1916201975699188" ORDER="544" O_E="0.0" SE="0.10897506576815842" STUDY_ID="STD-AFFIRM-2006" TOTAL_1="627" TOTAL_2="315" VAR="0.011875564959174453" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.82551474561183" CI_START="0.04726559097585214" DF="0" EFFECT_SIZE="0.19753086419753085" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" I2="0.0" ID="CMP-001.03.06" LOG_CI_END="-0.08327516482316803" LOG_CI_START="-1.325454907622282" LOG_EFFECT_SIZE="-0.704365036222725" NO="6" P_CHI2="1.0" P_Z="0.026232380827145615" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="24" WEIGHT="100.0" Z="2.2227541722020367">
<NAME>Mitoxantrone versus placebo</NAME>
<DICH_DATA CI_END="0.82551474561183" CI_START="0.04726559097585214" EFFECT_SIZE="0.19753086419753085" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.08327516482316803" LOG_CI_START="-1.325454907622282" LOG_EFFECT_SIZE="-0.704365036222725" ORDER="545" O_E="0.0" SE="0.7296625298090944" STUDY_ID="STD-Millefiorini-1997" TOTAL_1="27" TOTAL_2="24" VAR="0.5324074074074076" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.318949618975929" CI_END="0.9870748868732347" CI_START="0.759522780355075" DF="1" EFFECT_SIZE="0.8658555667642441" ESTIMABLE="YES" EVENTS_1="518" EVENTS_2="293" I2="24.182092658214714" ID="CMP-001.03.07" LOG_CI_END="-0.005649897257349621" LOG_CI_START="-0.11945919581813051" LOG_EFFECT_SIZE="-0.06255454653774006" NO="7" P_CHI2="0.25078078351916533" P_Z="0.03119603820090132" STUDIES="2" TAU2="0.002195674598133727" TOTAL_1="1582" TOTAL_2="773" WEIGHT="100.0" Z="2.1545631127447304">
<NAME>Fingolimod versus placebo</NAME>
<DICH_DATA CI_END="0.9568693313237138" CI_START="0.6736344366035969" EFFECT_SIZE="0.8028574798241033" ESTIMABLE="YES" EVENTS_1="228" EVENTS_2="139" LOG_CI_END="-0.019147364793324732" LOG_CI_START="-0.17157571954189754" LOG_EFFECT_SIZE="-0.09536154216761114" ORDER="12" O_E="0.0" SE="0.0895371701118366" STUDY_ID="STD-FREEDOMS-2010" TOTAL_1="854" TOTAL_2="418" VAR="0.008016904831635963" WEIGHT="43.761807359801885" />
<DICH_DATA CI_END="1.065434718528977" CI_START="0.7914466713689063" EFFECT_SIZE="0.9182781504210076" ESTIMABLE="YES" EVENTS_1="290" EVENTS_2="154" LOG_CI_END="0.027526844710762208" LOG_CI_START="-0.10157834310166242" LOG_EFFECT_SIZE="-0.03702574919545007" ORDER="151" O_E="0.0" SE="0.07583702640200486" STUDY_ID="STD-FREEDOMS-II-2014" TOTAL_1="728" TOTAL_2="355" VAR="0.0057512545734983815" WEIGHT="56.23819264019812" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.232167730332415E-30" CI_END="1.0091415222937679" CI_START="0.7541307195019924" DF="0" EFFECT_SIZE="0.8723672519568436" ESTIMABLE="YES" EVENTS_1="284" EVENTS_2="163" I2="100.0" ID="CMP-001.03.08" LOG_CI_END="0.00395207608953628" LOG_CI_START="-0.12255336787313896" LOG_EFFECT_SIZE="-0.05930064589180133" NO="8" P_CHI2="0.0" P_Z="0.06613552521825126" STUDIES="1" TAU2="0.0" TOTAL_1="725" TOTAL_2="363" WEIGHT="100.0" Z="1.8375040087948462">
<NAME>Teriflunomide versus placebo</NAME>
<DICH_DATA CI_END="1.0091415222937679" CI_START="0.7541307195019924" EFFECT_SIZE="0.8723672519568436" ESTIMABLE="YES" EVENTS_1="284" EVENTS_2="163" LOG_CI_END="0.00395207608953628" LOG_CI_START="-0.12255336787313896" LOG_EFFECT_SIZE="-0.05930064589180133" ORDER="36" O_E="0.0" SE="0.07430992399572246" STUDY_ID="STD-TEMSO-2011" TOTAL_1="725" TOTAL_2="363" VAR="0.005521964804250049" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.33376550828230983" CI_END="0.8969127388917245" CI_START="0.7212542390529512" DF="1" EFFECT_SIZE="0.8043022535006656" ESTIMABLE="YES" EVENTS_1="514" EVENTS_2="321" I2="0.0" ID="CMP-001.03.09" LOG_CI_END="-0.04724980763735646" LOG_CI_START="-0.1419116213344512" LOG_EFFECT_SIZE="-0.09458071448590383" NO="9" P_CHI2="0.563450347350422" P_Z="8.981786889770086E-5" STUDIES="2" TAU2="0.0" TOTAL_1="1534" TOTAL_2="773" WEIGHT="100.0" Z="3.9165696659396785">
<NAME>Dimethyl fumarate versus placebo</NAME>
<DICH_DATA CI_END="0.9946566770397635" CI_START="0.7038482656032601" EFFECT_SIZE="0.8367122426528367" ESTIMABLE="YES" EVENTS_1="220" EVENTS_2="135" LOG_CI_END="-0.002326797643186444" LOG_CI_START="-0.1525209552239871" LOG_EFFECT_SIZE="-0.07742387643358677" ORDER="18" O_E="0.0" SE="0.08822479163603289" STUDY_ID="STD-CONFIRM-2012" TOTAL_1="707" TOTAL_2="363" VAR="0.00778361385922142" WEIGHT="39.72313934229381" />
<DICH_DATA CI_END="0.9017292970614272" CI_START="0.6810034101284765" EFFECT_SIZE="0.7836330303857706" ESTIMABLE="YES" EVENTS_1="294" EVENTS_2="186" LOG_CI_END="-0.044923819927476044" LOG_CI_START="-0.16685071334966436" LOG_EFFECT_SIZE="-0.10588726663857018" ORDER="19" O_E="0.0" SE="0.07162046074404975" STUDY_ID="STD-DEFINE-2012" TOTAL_1="827" TOTAL_2="410" VAR="0.005129490397189971" WEIGHT="60.27686065770619" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0025744331335842323" CI_END="0.9495260008236556" CI_START="0.7287562602461612" DF="1" EFFECT_SIZE="0.8318491554162574" ESTIMABLE="YES" EVENTS_1="276" EVENTS_2="339" I2="0.0" ID="CMP-001.03.10" LOG_CI_END="-0.02249313849975691" LOG_CI_START="-0.13741770149030785" LOG_EFFECT_SIZE="-0.07995541999503236" NO="10" P_CHI2="0.9595336190069012" P_Z="0.006387899549347705" STUDIES="2" TAU2="0.0" TOTAL_1="984" TOTAL_2="1006" WEIGHT="100.0" Z="2.727175800910755">
<NAME>Laquinimod versus placebo</NAME>
<DICH_DATA CI_END="0.9857972791192695" CI_START="0.6979227122240153" EFFECT_SIZE="0.8294638694638695" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="195" LOG_CI_END="-0.006212384867760367" LOG_CI_START="-0.15619266836979878" LOG_EFFECT_SIZE="-0.08120252661877958" ORDER="77" O_E="0.0" SE="0.08809916094347423" STUDY_ID="STD-ALLEGRO-2012" TOTAL_1="550" TOTAL_2="556" VAR="0.007761462158944175" WEIGHT="58.716124352685405" />
<DICH_DATA CI_END="1.026243023780876" CI_START="0.6798081155857087" EFFECT_SIZE="0.8352534562211982" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="144" LOG_CI_END="0.011250217880220308" LOG_CI_START="-0.16761365509121673" LOG_EFFECT_SIZE="-0.07818171860549819" ORDER="139" O_E="0.0" SE="0.10506552437387275" STUDY_ID="STD-BRAVO-2014" TOTAL_1="434" TOTAL_2="450" VAR="0.011038764411956847" WEIGHT="41.2838756473146" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3435806491742657" CI_START="0.30910585250728945" DF="0" EFFECT_SIZE="0.6444444444444445" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" I2="0.0" ID="CMP-001.03.11" LOG_CI_END="0.12826374031896048" LOG_CI_START="-0.5098927720717356" LOG_EFFECT_SIZE="-0.19081451587638756" NO="11" P_CHI2="1.0" P_Z="0.24115950362005945" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="29" WEIGHT="100.0" Z="1.1720935901573935">
<NAME>Azathioprine versus placebo</NAME>
<DICH_DATA CI_END="1.3435806491742657" CI_START="0.30910585250728945" EFFECT_SIZE="0.6444444444444445" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.12826374031896048" LOG_CI_START="-0.5098927720717356" LOG_EFFECT_SIZE="-0.19081451587638756" ORDER="546" O_E="0.0" SE="0.37485629430397766" STUDY_ID="STD-Goodkin-1991" TOTAL_1="30" TOTAL_2="29" VAR="0.14051724137931032" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4146754695210583" CI_END="1.2377963777037224" CI_START="0.39252268858111905" DF="1" EFFECT_SIZE="0.6970388526418276" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="23" I2="0.0" ID="CMP-001.03.12" LOG_CI_END="0.09264920743614001" LOG_CI_START="-0.40613523512051164" LOG_EFFECT_SIZE="-0.15674301384218578" NO="12" P_CHI2="0.5196059264301609" P_Z="0.21800985802025763" STUDIES="2" TAU2="0.0" TOTAL_1="95" TOTAL_2="95" WEIGHT="100.0" Z="1.2318373860429883">
<NAME>Immunoglobulins versus placebo</NAME>
<DICH_DATA CI_END="3.454197176819389" CI_START="0.2895028710899463" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5383471248818377" LOG_CI_START="-0.5383471248818377" LOG_EFFECT_SIZE="0.0" ORDER="548" O_E="0.0" SE="0.6324555320336759" STUDY_ID="STD-Achiron-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.4" WEIGHT="21.460558043403374" />
<DICH_DATA CI_END="1.2073614434351951" CI_START="0.33038322445022916" EFFECT_SIZE="0.631578947368421" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.08183730273270702" LOG_CI_START="-0.48098201254311534" LOG_EFFECT_SIZE="-0.19957235490520417" ORDER="547" O_E="0.0" SE="0.3306028517935607" STUDY_ID="STD-Fazekas-1997" TOTAL_1="75" TOTAL_2="75" VAR="0.10929824561403506" WEIGHT="78.53944195659663" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.8297767807112795" CI_START="1.2939300177896724" DF="0" EFFECT_SIZE="2.226086956521739" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="15" I2="0.0" ID="CMP-001.03.13" LOG_CI_END="0.5831734617674585" LOG_CI_START="0.11191078814901731" LOG_EFFECT_SIZE="0.3475421249582379" NO="13" P_CHI2="1.0" P_Z="0.0038422636454943544" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="96" WEIGHT="100.0" Z="2.8908296207654933">
<NAME>Interferon beta-1a (Avonex) versus interferon beta-1b (Betaseron)</NAME>
<DICH_DATA CI_END="3.8297767807112795" CI_START="1.2939300177896724" EFFECT_SIZE="2.226086956521739" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="15" LOG_CI_END="0.5831734617674585" LOG_CI_START="0.11191078814901731" LOG_EFFECT_SIZE="0.3475421249582379" ORDER="549" O_E="0.0" SE="0.2768220272713295" STUDY_ID="STD-INCOMIN-2002" TOTAL_1="92" TOTAL_2="96" VAR="0.07663043478260868" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.980410425619734E-31" CI_END="1.2501450378197319" CI_START="0.7841487034748902" DF="0" EFFECT_SIZE="0.9901008082826265" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="77" I2="100.0" ID="CMP-001.03.14" LOG_CI_END="0.09696040138464629" LOG_CI_START="-0.10560157127637776" LOG_EFFECT_SIZE="-0.004320584945865737" NO="14" P_CHI2="0.0" P_Z="0.9333658280841384" STUDIES="1" TAU2="0.0" TOTAL_1="143" TOTAL_2="158" WEIGHT="100.0" Z="0.08361086510757693">
<NAME>Interferon beta-1a (Rebif) versus interferon beta-1b (Betaseron)</NAME>
<DICH_DATA CI_END="1.2501450378197319" CI_START="0.7841487034748902" EFFECT_SIZE="0.9901008082826265" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="77" LOG_CI_END="0.09696040138464629" LOG_CI_START="-0.10560157127637776" LOG_EFFECT_SIZE="-0.004320584945865737" ORDER="550" O_E="0.0" SE="0.1189859054390215" STUDY_ID="STD-Koch_x002d_Henriksen-2006" TOTAL_1="143" TOTAL_2="158" VAR="0.014157645693143768" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8389534505407884" CI_END="1.1301031117032543" CI_START="0.8644697459835397" DF="1" EFFECT_SIZE="0.9884027265792623" ESTIMABLE="YES" EVENTS_1="175" EVENTS_2="679" I2="0.0" ID="CMP-001.03.15" LOG_CI_END="0.053118070740726844" LOG_CI_START="-0.06325020121286742" LOG_EFFECT_SIZE="-0.005066065236070285" NO="15" P_CHI2="0.35969632900908544" P_Z="0.8644965124418693" STUDIES="2" TAU2="0.0" TOTAL_1="487" TOTAL_2="1832" WEIGHT="100.0" Z="0.17065313833976695">
<NAME>Glatiramer acetate versus interferon beta-1b (Betaseron)</NAME>
<DICH_DATA CI_END="3.334380257354832" CI_START="0.6310299204321983" EFFECT_SIZE="1.4505494505494505" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.5230151258620951" LOG_CI_START="-0.1999500480925826" LOG_EFFECT_SIZE="0.16153253888475624" ORDER="81" O_E="0.0" SE="0.42467332191630586" STUDY_ID="STD-BECOME-2009" TOTAL_1="39" TOTAL_2="36" VAR="0.18034743034743034" WEIGHT="2.5908031455397653" />
<DICH_DATA CI_END="1.120613155457509" CI_START="0.8541813208456013" EFFECT_SIZE="0.9783694727891157" ESTIMABLE="YES" EVENTS_1="164" EVENTS_2="672" LOG_CI_END="0.04945571656905356" LOG_CI_START="-0.06844992991502515" LOG_EFFECT_SIZE="-0.009497106672985782" ORDER="552" O_E="0.0" SE="0.06925836038711077" STUDY_ID="STD-BEYOND-2009" TOTAL_1="448" TOTAL_2="1796" VAR="0.004796720483510913" WEIGHT="97.40919685446023" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8508800107673538" CI_START="0.39054888137972704" DF="0" EFFECT_SIZE="0.5764635603345281" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="62" I2="0.0" ID="CMP-001.03.16" LOG_CI_END="-0.0701316788528022" LOG_CI_START="-0.408324601774095" LOG_EFFECT_SIZE="-0.23922814031344863" NO="16" P_CHI2="1.0" P_Z="0.005556831767696926" STUDIES="1" TAU2="0.0" TOTAL_1="378" TOTAL_2="386" WEIGHT="100.0" Z="2.7728465460051948">
<NAME>Glatiramer acetate versus interferon beta-1a (Rebif)</NAME>
<DICH_DATA CI_END="0.8508800107673538" CI_START="0.39054888137972704" EFFECT_SIZE="0.5764635603345281" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="62" LOG_CI_END="-0.0701316788528022" LOG_CI_START="-0.408324601774095" LOG_EFFECT_SIZE="-0.23922814031344863" ORDER="553" O_E="0.0" SE="0.19865619700593512" STUDY_ID="STD-REGARD-2008" TOTAL_1="378" TOTAL_2="386" VAR="0.0394642846088609" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2199555276535352" CI_START="0.8348752352559644" DF="0" EFFECT_SIZE="1.0092128904010091" ESTIMABLE="YES" EVENTS_1="220" EVENTS_2="111" I2="0.0" ID="CMP-001.03.17" LOG_CI_END="0.08634399916105859" LOG_CI_START="-0.07837842114918528" LOG_EFFECT_SIZE="0.003982789005936632" NO="17" P_CHI2="1.0" P_Z="0.9244902721384071" STUDIES="1" TAU2="0.0" TOTAL_1="707" TOTAL_2="360" WEIGHT="100.0" Z="0.09477911986668926">
<NAME>Dimethyl fumarate versus glatiramer acetate</NAME>
<DICH_DATA CI_END="1.2199555276535352" CI_START="0.8348752352559644" EFFECT_SIZE="1.0092128904010091" ESTIMABLE="YES" EVENTS_1="220" EVENTS_2="111" LOG_CI_END="0.08634399916105859" LOG_CI_START="-0.07837842114918528" LOG_EFFECT_SIZE="0.003982789005936632" ORDER="91" O_E="0.0" SE="0.09675876507936819" STUDY_ID="STD-CONFIRM-2012" TOTAL_1="707" TOTAL_2="360" VAR="0.009362258619684361" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.2121871790681262" CI_END="0.5360628019536164" CI_START="0.3155124386246613" DF="2" EFFECT_SIZE="0.41125962833756774" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="166" I2="37.7371277417211" ID="CMP-001.03.18" LOG_CI_END="-0.2707843279486781" LOG_CI_START="-0.5009835146462561" LOG_EFFECT_SIZE="-0.3858839212974671" NO="18" P_CHI2="0.2006701249060252" P_Z="4.9980909390376064E-11" STUDIES="3" TAU2="0.020954203217503162" TOTAL_1="1045" TOTAL_2="537" WEIGHT="100.0" Z="6.570992702504467">
<NAME>Alemtuzumab versus interferon beta-1a (Rebif)</NAME>
<DICH_DATA CI_END="0.52164662918465" CI_START="0.23118807264138144" EFFECT_SIZE="0.3472729168839295" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="43" LOG_CI_END="-0.2826235946295326" LOG_CI_START="-0.636034575613322" LOG_EFFECT_SIZE="-0.4593290851214273" ORDER="47" O_E="0.0" SE="0.20759535964244788" STUDY_ID="STD-CAMMS223-2008" TOTAL_1="223" TOTAL_2="111" VAR="0.04309583334507727" WEIGHT="28.54719172965911" />
<DICH_DATA CI_END="0.8432686895100163" CI_START="0.37161471564468884" EFFECT_SIZE="0.5597955468421789" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="37" LOG_CI_END="-0.07403402468827482" LOG_CI_START="-0.42990709662471815" LOG_EFFECT_SIZE="-0.2519705606564965" ORDER="30" O_E="0.0" SE="0.2090416040555836" STUDY_ID="STD-CARE_x002d_MS-I-2012" TOTAL_1="386" TOTAL_2="195" VAR="0.04369839222613139" WEIGHT="28.281133363589998" />
<DICH_DATA CI_END="0.5005798210342993" CI_START="0.2821242451435251" EFFECT_SIZE="0.37580008534243653" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="86" LOG_CI_END="-0.3005266613000844" LOG_CI_START="-0.5495595899184005" LOG_EFFECT_SIZE="-0.4250431256092424" ORDER="35" O_E="0.0" SE="0.14628317500327678" STUDY_ID="STD-CARE_x002d_MS-II-2012" TOTAL_1="436" TOTAL_2="231" VAR="0.021398767289039302" WEIGHT="43.17167490675089" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3339496597333247" CI_START="0.8530531279358037" DF="0" EFFECT_SIZE="1.0667379855167873" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="112" I2="0.0" ID="CMP-001.03.19" LOG_CI_END="0.1251394405906124" LOG_CI_START="-0.06902392023828714" LOG_EFFECT_SIZE="0.028057760176162627" NO="19" P_CHI2="1.0" P_Z="0.5710859449855029" STUDIES="1" TAU2="0.0" TOTAL_1="434" TOTAL_2="447" WEIGHT="100.0" Z="0.5664529002523924">
<NAME>Laquinimod versus interferon beta-1a (Avonex)</NAME>
<DICH_DATA CI_END="1.3339496597333247" CI_START="0.8530531279358036" EFFECT_SIZE="1.0667379855167873" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="112" LOG_CI_END="0.1251394405906124" LOG_CI_START="-0.0690239202382872" LOG_EFFECT_SIZE="0.028057760176162627" ORDER="141" O_E="0.0" SE="0.11405251927503254" STUDY_ID="STD-BRAVO-2014" TOTAL_1="434" TOTAL_2="447" VAR="0.01300797715298167" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2273623076891358" CI_START="0.4861936935236003" DF="0" EFFECT_SIZE="0.7724867724867724" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="27" I2="0.0" ID="CMP-001.03.20" LOG_CI_END="0.0889727819640686" LOG_CI_START="-0.31319067874168277" LOG_EFFECT_SIZE="-0.11210894838880707" NO="20" P_CHI2="1.0" P_Z="0.27450918770980215" STUDIES="1" TAU2="0.0" TOTAL_1="77" TOTAL_2="73" WEIGHT="100.00000000000001" Z="1.092737270567153">
<NAME>Azathioprine versus interferons beta (Avonex, Rebif or Betaseron)</NAME>
<DICH_DATA CI_END="1.2273623076891358" CI_START="0.4861936935236003" EFFECT_SIZE="0.7724867724867724" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="27" LOG_CI_END="0.0889727819640686" LOG_CI_START="-0.31319067874168277" LOG_EFFECT_SIZE="-0.11210894838880707" ORDER="180" O_E="0.0" SE="0.23623280755979512" STUDY_ID="STD-MAIN-TRIAL" TOTAL_1="77" TOTAL_2="73" VAR="0.0558059393675832" WEIGHT="100.00000000000001" />
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Treatment acceptability within pairwise comparisons</NAME>
<DICH_OUTCOME CHI2="46.129192828546856" CI_END="2.0398926726166575" CI_START="1.4231228759369932" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7038245000166585" ESTIMABLE="YES" EVENTS_1="343" EVENTS_2="185" I2="58.811332184763636" I2_Q="60.799234743429466" ID="CMP-002.01" LOG_CI_END="0.3096073179570064" LOG_CI_START="0.15324239975928372" LOG_EFFECT_SIZE="0.23142485885814504" METHOD="MH" NO="1" P_CHI2="4.7519068816992416E-4" P_Q="3.050092103927815E-4" P_Z="6.5679923827686E-9" Q="45.91747095289926" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.25476885496513196" TOTALS="SUB" TOTAL_1="5205" TOTAL_2="4650" WEIGHT="1900.0" Z="5.801613222675363">
<NAME>Comparisons for treatment discontinuation due to AEs over 12 months</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.000920319981587" CI_START="0.668922933247591" DF="0" EFFECT_SIZE="3.167721518987342" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="1.176117904230926" LOG_CI_START="-0.17462391450909617" LOG_EFFECT_SIZE="0.5007469948609149" NO="1" P_CHI2="1.0" P_Z="0.1461694364568714" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="143" WEIGHT="100.0" Z="1.453195661343415">
<NAME>Interferon beta-1a (Avonex) 30 µg versus placebo</NAME>
<DICH_DATA CI_END="15.000920319981587" CI_START="0.668922933247591" EFFECT_SIZE="3.1677215189873418" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.176117904230926" LOG_CI_START="-0.17462391450909617" LOG_EFFECT_SIZE="0.5007469948609148" ORDER="540" O_E="0.0" SE="0.7934324306077267" STUDY_ID="STD-MSCRG-1996" TOTAL_1="158" TOTAL_2="143" VAR="0.6295350219400851" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="76.53714473748501" CI_START="0.13015790041121086" DF="0" EFFECT_SIZE="3.15625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="1.883872256583486" LOG_CI_START="-0.8855294656580126" LOG_EFFECT_SIZE="0.4991713954627366" NO="2" P_CHI2="1.0" P_Z="0.4798472690431431" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="100" WEIGHT="100.0" Z="0.7065482406270052">
<NAME>Interferon beta-1a (Rebif) 22 µg versus placebo</NAME>
<DICH_DATA CI_END="76.53714473748501" CI_START="0.13015790041121086" EFFECT_SIZE="3.15625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.883872256583486" LOG_CI_START="-0.8855294656580126" LOG_EFFECT_SIZE="0.4991713954627366" ORDER="185" O_E="0.0" SE="1.6267602804042733" STUDY_ID="STD-OWIMS-1999" TOTAL_1="95" TOTAL_2="100" VAR="2.64634900990099" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="200.26744706601465" CI_START="0.6288504370029993" DF="0" EFFECT_SIZE="11.222222222222223" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="2.301610361632326" LOG_CI_START="-0.20145263294569019" LOG_EFFECT_SIZE="1.0500788643433177" NO="3" P_CHI2="1.0" P_Z="0.1000773827122768" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="100" WEIGHT="100.0" Z="1.6444785924267928">
<NAME>Interferon beta-1a (Rebif) 44 µg versus placebo</NAME>
<DICH_DATA CI_END="200.26744706601465" CI_START="0.6288504370029993" EFFECT_SIZE="11.222222222222221" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.301610361632326" LOG_CI_START="-0.20145263294569019" LOG_EFFECT_SIZE="1.0500788643433177" ORDER="185" O_E="0.0" SE="1.4703115933767787" STUDY_ID="STD-OWIMS-1999" TOTAL_1="98" TOTAL_2="100" VAR="2.161816181618162" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.890375199741175" CI_START="0.25735404431539344" DF="0" EFFECT_SIZE="1.5126050420168067" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-002.01.04" LOG_CI_END="0.9489200898497112" LOG_CI_START="-0.5894690024281607" LOG_EFFECT_SIZE="0.1797255437107753" NO="4" P_CHI2="1.0" P_Z="0.6469856093597282" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="120" WEIGHT="100.0" Z="0.4579538356624966">
<NAME>Glatiramer acetate 20 mg daily versus placebo</NAME>
<DICH_DATA CI_END="8.890375199741175" CI_START="0.25735404431539344" EFFECT_SIZE="1.5126050420168067" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9489200898497112" LOG_CI_START="-0.5894690024281607" LOG_EFFECT_SIZE="0.1797255437107753" ORDER="160" O_E="0.0" SE="0.9036573679528442" STUDY_ID="STD-Comi-2001" TOTAL_1="119" TOTAL_2="120" VAR="0.8165966386554622" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.650931239776006" CI_START="0.9879886091186162" DF="0" EFFECT_SIZE="2.3628490632732415" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="6" I2="0.0" ID="CMP-002.01.05" LOG_CI_END="0.7521200228584124" LOG_CI_START="-0.005248062523147952" LOG_EFFECT_SIZE="0.37343598016763224" NO="5" P_CHI2="1.0" P_Z="0.05326066008498658" STUDIES="1" TAU2="0.0" TOTAL_1="943" TOTAL_2="461" WEIGHT="100.0" Z="1.9328014628216952">
<NAME>Glatiramer 40 mg three times per week versus placebo</NAME>
<DICH_DATA CI_END="5.650931239776006" CI_START="0.9879886091186162" EFFECT_SIZE="2.3628490632732415" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="6" LOG_CI_END="0.7521200228584124" LOG_CI_START="-0.005248062523147952" LOG_EFFECT_SIZE="0.37343598016763224" ORDER="67" O_E="0.0" SE="0.4448817623856148" STUDY_ID="STD-GALA-2013" TOTAL_1="943" TOTAL_2="461" VAR="0.19791978250333062" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.2405659889041365" CI_START="1.3087765628384065" DF="0" EFFECT_SIZE="2.0594117647058825" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="25" I2="0.0" ID="CMP-002.01.06" LOG_CI_END="0.5106208695864659" LOG_CI_START="0.11686550918705153" LOG_EFFECT_SIZE="0.3137431893867587" NO="6" P_CHI2="1.0" P_Z="0.0017878199311917628" STUDIES="1" TAU2="0.0" TOTAL_1="408" TOTAL_2="389" WEIGHT="100.0" Z="3.123387836391679">
<NAME>Teriflunomide 7 mg versus placebo</NAME>
<DICH_DATA CI_END="3.2405659889041365" CI_START="1.3087765628384065" EFFECT_SIZE="2.0594117647058825" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="25" LOG_CI_END="0.5106208695864659" LOG_CI_START="0.11686550918705153" LOG_EFFECT_SIZE="0.3137431893867587" ORDER="99" O_E="0.0" SE="0.23129384781908502" STUDY_ID="STD-TOWER-2014" TOTAL_1="408" TOTAL_2="389" VAR="0.05349684403895806" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.9139320685199306" CI_START="1.6092463126477716" DF="0" EFFECT_SIZE="2.509677419354839" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="25" I2="0.0" ID="CMP-002.01.07" LOG_CI_END="0.5926132836308823" LOG_CI_START="0.20662252267995027" LOG_EFFECT_SIZE="0.3996179031554163" NO="7" P_CHI2="1.0" P_Z="4.9427354234049726E-5" STUDIES="1" TAU2="0.0" TOTAL_1="372" TOTAL_2="389" WEIGHT="100.0" Z="4.05831836923992">
<NAME>Teriflunomide 14 mg versus placebo</NAME>
<DICH_DATA CI_END="3.9139320685199306" CI_START="1.6092463126477716" EFFECT_SIZE="2.509677419354839" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="25" LOG_CI_END="0.5926132836308823" LOG_CI_START="0.20662252267995027" LOG_EFFECT_SIZE="0.3996179031554163" ORDER="99" O_E="0.0" SE="0.22673288366765929" STUDY_ID="STD-TOWER-2014" TOTAL_1="372" TOTAL_2="389" VAR="0.051407800536252324" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.890828991338901" CI_START="1.3098410077869702" DF="0" EFFECT_SIZE="2.7777777777777777" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="9" I2="0.0" ID="CMP-002.01.08" LOG_CI_END="0.7701764155053277" LOG_CI_START="0.11721858296009764" LOG_EFFECT_SIZE="0.44369749923271273" NO="8" P_CHI2="1.0" P_Z="0.007729403308981137" STUDIES="1" TAU2="0.0" TOTAL_1="500" TOTAL_2="500" WEIGHT="100.0" Z="2.663667009358882">
<NAME>Pegylated interferon beta-1a every 4 weeks versus placebo</NAME>
<DICH_DATA CI_END="5.890828991338901" CI_START="1.3098410077869702" EFFECT_SIZE="2.7777777777777777" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="9" LOG_CI_END="0.7701764155053277" LOG_CI_START="0.11721858296009764" LOG_EFFECT_SIZE="0.44369749923271273" ORDER="103" O_E="0.0" SE="0.38355066303046736" STUDY_ID="STD-ADVANCE-2014" TOTAL_1="500" TOTAL_2="500" VAR="0.1471111111111111" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.960057732377083" CI_START="1.335399770342559" DF="0" EFFECT_SIZE="2.8211805555555554" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="9" I2="0.0" ID="CMP-002.01.09" LOG_CI_END="0.7752504665743571" LOG_CI_START="0.12561129720900502" LOG_EFFECT_SIZE="0.4504308818916811" NO="9" P_CHI2="1.0" P_Z="0.006569698365938469" STUDIES="1" TAU2="0.0" TOTAL_1="512" TOTAL_2="500" WEIGHT="100.0" Z="2.7179035614332356">
<NAME>Pegylated interferon beta-1a every 2 weeks versus placebo</NAME>
<DICH_DATA CI_END="5.960057732377083" CI_START="1.335399770342559" EFFECT_SIZE="2.8211805555555554" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="9" LOG_CI_END="0.7752504665743571" LOG_CI_START="0.12561129720900502" LOG_EFFECT_SIZE="0.4504308818916811" ORDER="103" O_E="0.0" SE="0.38160126385095944" STUDY_ID="STD-ADVANCE-2014" TOTAL_1="512" TOTAL_2="500" VAR="0.14561952457264957" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.328292007281494" CI_START="0.721653953397895" DF="0" EFFECT_SIZE="3.432692307692307" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" ID="CMP-002.01.10" LOG_CI_END="1.2129407584900482" LOG_CI_START="-0.14167100486322257" LOG_EFFECT_SIZE="0.5356348768134127" NO="10" P_CHI2="1.0" P_Z="0.12114117905647073" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="204" WEIGHT="100.0" Z="1.5500014038251824">
<NAME>Daclizumab 150 mg versus placebo</NAME>
<DICH_DATA CI_END="16.328292007281494" CI_START="0.721653953397895" EFFECT_SIZE="3.4326923076923075" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.2129407584900482" LOG_CI_START="-0.14167100486322257" LOG_EFFECT_SIZE="0.5356348768134128" ORDER="63" O_E="0.0" SE="0.7957056552300836" STUDY_ID="STD-SELECT-2013" TOTAL_1="208" TOTAL_2="204" VAR="0.6331474897651368" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.082440046005768" CI_START="0.9606746063460248" DF="0" EFFECT_SIZE="4.392344497607654" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" I2="0.0" ID="CMP-002.01.11" LOG_CI_END="1.3028164790972758" LOG_CI_START="-0.01742368891689915" LOG_EFFECT_SIZE="0.6426963950901883" NO="11" P_CHI2="1.0" P_Z="0.056361331503635016" STUDIES="1" TAU2="0.0" TOTAL_1="209" TOTAL_2="204" WEIGHT="100.0" Z="1.908231271686274">
<NAME>Daclizumab 300 mg versus placebo</NAME>
<DICH_DATA CI_END="20.082440046005768" CI_START="0.960674606346025" EFFECT_SIZE="4.392344497607655" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.3028164790972758" LOG_CI_START="-0.01742368891689905" LOG_EFFECT_SIZE="0.6426963950901884" ORDER="62" O_E="0.0" SE="0.7755156099857579" STUDY_ID="STD-SELECT-2013" TOTAL_1="209" TOTAL_2="204" VAR="0.6014244613315821" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.12143335736790362" CI_END="19.959830574076506" CI_START="0.22971159191042023" DF="1" EFFECT_SIZE="2.141262350912048" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-002.01.12" LOG_CI_END="1.3001568505257033" LOG_CI_START="-0.6388170884980285" LOG_EFFECT_SIZE="0.3306698810138374" NO="12" P_CHI2="0.7274851285083785" P_Z="0.5038151322869293" STUDIES="2" TAU2="0.0" TOTAL_1="104" TOTAL_2="59" WEIGHT="100.00000000000001" Z="0.668498987547593">
<NAME>Immunoglobulins 0.2 g versus placebo</NAME>
<DICH_DATA CI_END="34.41095271111275" CI_START="0.05957705742692382" EFFECT_SIZE="1.4318181818181819" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5366966967840037" LOG_CI_START="-1.2249209508492152" LOG_EFFECT_SIZE="0.1558878729673943" ORDER="604" O_E="0.0" SE="1.6221878764475792" STUDY_ID="STD-Fazekas-2008" TOTAL_1="87" TOTAL_2="41" VAR="2.6314935064935066" WEIGHT="49.29658618854162" />
<DICH_DATA CI_END="72.79814524297626" CI_START="0.13774770970205838" EFFECT_SIZE="3.1666666666666665" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8621203144641083" LOG_CI_START="-0.8609156133257376" LOG_EFFECT_SIZE="0.5006023505691853" ORDER="195" O_E="0.0" SE="1.5995247832289885" STUDY_ID="STD-Lewanska-2002" TOTAL_1="17" TOTAL_2="18" VAR="2.5584795321637426" WEIGHT="50.7034138114584" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="76.92616453299082" CI_START="0.1461429229069466" DF="0" EFFECT_SIZE="3.3529411764705883" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.01.13" LOG_CI_END="1.8860740794586417" LOG_CI_START="-0.835222210870207" LOG_EFFECT_SIZE="0.5254259342942175" NO="13" P_CHI2="1.0" P_Z="0.44913561834766913" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="18" WEIGHT="100.0" Z="0.7568568784074073">
<NAME>Immunoglobulins 0.4 g versus placebo</NAME>
<DICH_DATA CI_END="76.92616453299082" CI_START="0.1461429229069466" EFFECT_SIZE="3.3529411764705883" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8860740794586417" LOG_CI_START="-0.835222210870207" LOG_EFFECT_SIZE="0.5254259342942175" ORDER="195" O_E="0.0" SE="1.5985029115730547" STUDY_ID="STD-Lewanska-2002" TOTAL_1="16" TOTAL_2="18" VAR="2.5552115583075334" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9697958469788481" CI_START="0.562308927159742" DF="0" EFFECT_SIZE="1.0524418223533267" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" I2="0.0" ID="CMP-002.01.14" LOG_CI_END="0.2944212174687199" LOG_CI_START="-0.250025021620529" LOG_EFFECT_SIZE="0.022198097924095446" NO="14" P_CHI2="1.0" P_Z="0.8730206305956261" STUDIES="1" TAU2="0.0" TOTAL_1="339" TOTAL_2="338" WEIGHT="100.0" Z="0.15982284138577144">
<NAME>Interferon beta-1a (Rebif) 44 µg versus interferon beta-1a (Avonex) 30 µg</NAME>
<DICH_DATA CI_END="1.969795846978848" CI_START="0.562308927159742" EFFECT_SIZE="1.0524418223533267" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.29442121746871985" LOG_CI_START="-0.250025021620529" LOG_EFFECT_SIZE="0.022198097924095446" ORDER="201" O_E="0.0" SE="0.3198104158933735" STUDY_ID="STD-EVIDENCE-2007" TOTAL_1="339" TOTAL_2="338" VAR="0.10227870211389253" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.540155353835221" CI_START="0.8098116522493903" DF="0" EFFECT_SIZE="1.4342410550738796" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="19" I2="0.0" ID="CMP-002.01.15" LOG_CI_END="0.40486027852944706" LOG_CI_START="-0.09161597852931892" LOG_EFFECT_SIZE="0.15662215000006408" NO="15" P_CHI2="1.0" P_Z="0.21623189768655515" STUDIES="1" TAU2="0.0" TOTAL_1="431" TOTAL_2="435" WEIGHT="100.0" Z="1.2366100848404533">
<NAME>Fingolimod 0.5 mg versus interferon beta-1a (Avonex) 30 µg</NAME>
<DICH_DATA CI_END="2.540155353835221" CI_START="0.8098116522493903" EFFECT_SIZE="1.4342410550738796" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="19" LOG_CI_END="0.40486027852944706" LOG_CI_START="-0.09161597852931892" LOG_EFFECT_SIZE="0.15662215000006408" ORDER="25" O_E="0.0" SE="0.2916326109934272" STUDY_ID="STD-TRASFORMS-2010" TOTAL_1="431" TOTAL_2="435" VAR="0.08504957979484362" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.9822531668790497" CI_START="1.4041988093797246" DF="0" EFFECT_SIZE="2.3647146034099333" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="19" I2="0.0" ID="CMP-002.01.16" LOG_CI_END="0.6001288663100652" LOG_CI_START="0.1474286004604886" LOG_EFFECT_SIZE="0.3737787333852769" NO="16" P_CHI2="1.0" P_Z="0.0012098527887102115" STUDIES="1" TAU2="0.0" TOTAL_1="426" TOTAL_2="435" WEIGHT="100.0" Z="3.2365470528155953">
<NAME>Fingolimod 1.25 mg versus interferon beta-1a (Avonex) 30 µg</NAME>
<DICH_DATA CI_END="3.9822531668790497" CI_START="1.4041988093797246" EFFECT_SIZE="2.3647146034099333" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="19" LOG_CI_END="0.6001288663100652" LOG_CI_START="0.1474286004604886" LOG_EFFECT_SIZE="0.3737787333852769" ORDER="18" O_E="0.0" SE="0.2659183770624981" STUDY_ID="STD-TRASFORMS-2010" TOTAL_1="426" TOTAL_2="435" VAR="0.07071258325955292" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8079364968438487" CI_START="0.18857152489411072" DF="0" EFFECT_SIZE="0.390325271059216" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="22" I2="0.0" ID="CMP-002.01.17" LOG_CI_END="-0.09262277307952012" LOG_CI_START="-0.7245238869699292" LOG_EFFECT_SIZE="-0.4085733300247247" NO="17" P_CHI2="1.0" P_Z="0.011259538955886281" STUDIES="1" TAU2="0.0" TOTAL_1="109" TOTAL_2="104" WEIGHT="100.0" Z="2.5345390102633663">
<NAME>Teriflunomide 7 mg versus interferon beta-1a (Rebif) 44 µg</NAME>
<DICH_DATA CI_END="0.8079364968438487" CI_START="0.18857152489411072" EFFECT_SIZE="0.390325271059216" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="22" LOG_CI_END="-0.09262277307952012" LOG_CI_START="-0.7245238869699292" LOG_EFFECT_SIZE="-0.4085733300247247" ORDER="69" O_E="0.0" SE="0.37118184226018713" STUDY_ID="STD-TENERE-2014" TOTAL_1="109" TOTAL_2="104" VAR="0.13777596002366646" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9794679996213274" CI_START="0.26665369118156823" DF="0" EFFECT_SIZE="0.5110565110565111" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" I2="0.0" ID="CMP-002.01.18" LOG_CI_END="-0.009009748352143451" LOG_CI_START="-0.5740524001727735" LOG_EFFECT_SIZE="-0.2915310742624585" NO="18" P_CHI2="1.0" P_Z="0.04312800251441572" STUDIES="1" TAU2="0.0" TOTAL_1="111" TOTAL_2="104" WEIGHT="100.0" Z="2.0224682299207233">
<NAME>Teriflunomide 14 mg versus interferon beta-1a (Rebif) 44 µg</NAME>
<DICH_DATA CI_END="0.9794679996213274" CI_START="0.26665369118156823" EFFECT_SIZE="0.5110565110565111" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" LOG_CI_END="-0.009009748352143451" LOG_CI_START="-0.5740524001727735" LOG_EFFECT_SIZE="-0.2915310742624585" ORDER="70" O_E="0.0" SE="0.33190885068567416" STUDY_ID="STD-TENERE-2014" TOTAL_1="111" TOTAL_2="104" VAR="0.11016348516348515" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.703882650002728" CI_START="0.21259033747353795" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-002.01.19" LOG_CI_END="0.6724564786522703" LOG_CI_START="-0.6724564786522703" LOG_EFFECT_SIZE="0.0" NO="19" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="47" WEIGHT="100.0" Z="0.0">
<NAME>Azathioprine versus interferons beta (Avonex, Rebif or Betaseron)</NAME>
<DICH_DATA CI_END="4.703882650002728" CI_START="0.21259033747353795" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6724564786522703" LOG_CI_START="-0.6724564786522703" LOG_EFFECT_SIZE="0.0" ORDER="177" O_E="0.0" SE="0.7900085285471954" STUDY_ID="STD-Etemadifar-2007" TOTAL_1="47" TOTAL_2="47" VAR="0.6241134751773049" WEIGHT="100.0" />
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="76.23215480324018" CI_END="1.4090543093067698" CI_START="1.1560957962673564" CI_STUDY="95" CI_TOTAL="95" DF="37" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2763235341017418" ESTIMABLE="YES" EVENTS_1="974" EVENTS_2="762" I2="51.464050707343574" I2_Q="53.448526735885494" ID="CMP-002.02" LOG_CI_END="0.1489277324831656" LOG_CI_START="0.06299382203136848" LOG_EFFECT_SIZE="0.10596077725726707" METHOD="MH" NO="2" P_CHI2="1.5553619963926124E-4" P_Q="5.896858030128849E-4" P_Z="1.341763608616085E-6" Q="55.852152846992325" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="23" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.09195513034702743" TOTALS="SUB" TOTAL_1="11004" TOTAL_2="11284" WEIGHT="2700.0" Z="4.8334657670351815">
<NAME>Comparisons for treatment discontinuation due to AEs over 24 months</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="41.507027904699854" CI_START="0.5831879857931024" DF="0" EFFECT_SIZE="4.92" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="1.6181216369969293" LOG_CI_START="-0.23419143146220875" LOG_EFFECT_SIZE="0.6919651027673603" NO="1" P_CHI2="1.0" P_Z="0.14309558251271864" STUDIES="1" TAU2="0.0" TOTAL_1="125" TOTAL_2="123" WEIGHT="100.0" Z="1.4643601052934014">
<NAME>Interferon beta-1b (Betaseron) 50 µg versus placebo</NAME>
<DICH_DATA CI_END="41.507027904699854" CI_START="0.5831879857931024" EFFECT_SIZE="4.92" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6181216369969293" LOG_CI_START="-0.23419143146220875" LOG_EFFECT_SIZE="0.6919651027673603" ORDER="539" O_E="0.0" SE="1.088057865510464" STUDY_ID="STD-IFNB-MS-Group-1993" TOTAL_1="125" TOTAL_2="123" VAR="1.183869918699187" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="76.31942538163959" CI_START="1.2892340308409074" DF="0" EFFECT_SIZE="9.919354838709678" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="1.8826350918516652" LOG_CI_START="0.11033176070266039" LOG_EFFECT_SIZE="0.9964834262771629" NO="2" P_CHI2="1.0" P_Z="0.02752487139275206" STUDIES="1" TAU2="0.0" TOTAL_1="124" TOTAL_2="123" WEIGHT="100.0" Z="2.203992502150424">
<NAME>Interferon beta-1b (Betaseron) 250 µg versus placebo</NAME>
<DICH_DATA CI_END="76.31942538163959" CI_START="1.2892340308409074" EFFECT_SIZE="9.919354838709678" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.8826350918516652" LOG_CI_START="0.11033176070266039" LOG_EFFECT_SIZE="0.9964834262771629" ORDER="539" O_E="0.0" SE="1.0410597497599046" STUDY_ID="STD-IFNB-MS-Group-1993" TOTAL_1="124" TOTAL_2="123" VAR="1.083805402570155" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.535048088894267" CI_START="0.8073170146058768" DF="0" EFFECT_SIZE="1.4305898975626987" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="19" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="0.4039862021479867" LOG_CI_START="-0.09295589444885555" LOG_EFFECT_SIZE="0.15551515384956557" NO="3" P_CHI2="1.0" P_Z="0.21992833075711604" STUDIES="1" TAU2="0.0" TOTAL_1="447" TOTAL_2="450" WEIGHT="100.00000000000001" Z="1.2267187774298567">
<NAME>Interferon beta-1a (Avonex) 30 µg versus placebo</NAME>
<DICH_DATA CI_END="2.535048088894267" CI_START="0.8073170146058768" EFFECT_SIZE="1.4305898975626987" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="19" LOG_CI_END="0.4039862021479867" LOG_CI_START="-0.09295589444885555" LOG_EFFECT_SIZE="0.15551515384956557" ORDER="147" O_E="0.0" SE="0.2919062474440361" STUDY_ID="STD-BRAVO-2014" TOTAL_1="447" TOTAL_2="450" VAR="0.08520925729685884" WEIGHT="100.00000000000001" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.793119893227503" CI_START="0.6061361422197874" DF="0" EFFECT_SIZE="2.308641975308642" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-002.02.04" LOG_CI_END="0.9441429947562037" LOG_CI_START="-0.21742981944050524" LOG_EFFECT_SIZE="0.36335658765784923" NO="4" P_CHI2="1.0" P_Z="0.22011986026343133" STUDIES="1" TAU2="0.0" TOTAL_1="189" TOTAL_2="187" WEIGHT="100.0" Z="1.2262095266877562">
<NAME>Interferon beta-1a (Rebif) 22 µg versus placebo</NAME>
<DICH_DATA CI_END="8.793119893227503" CI_START="0.6061361422197874" EFFECT_SIZE="2.308641975308642" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9441429947562037" LOG_CI_START="-0.21742981944050524" LOG_EFFECT_SIZE="0.36335658765784923" ORDER="541" O_E="0.0" SE="0.68231362093731" STUDY_ID="STD-PRISMS-1998" TOTAL_1="189" TOTAL_2="187" VAR="0.46555187731658315" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.08375683117739" CI_START="0.8386931334097487" DF="0" EFFECT_SIZE="3.0489130434782608" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="0.0" ID="CMP-002.02.05" LOG_CI_END="1.0446869891386776" LOG_CI_START="-0.07639691264542782" LOG_EFFECT_SIZE="0.4841450382466249" NO="5" P_CHI2="1.0" P_Z="0.09048626551809509" STUDIES="1" TAU2="0.0" TOTAL_1="184" TOTAL_2="187" WEIGHT="100.0" Z="1.6928382197747216">
<NAME>Interferon beta-1a (Rebif) 44 µg versus placebo</NAME>
<DICH_DATA CI_END="11.08375683117739" CI_START="0.8386931334097487" EFFECT_SIZE="3.0489130434782608" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.0446869891386776" LOG_CI_START="-0.07639691264542782" LOG_EFFECT_SIZE="0.4841450382466249" ORDER="541" O_E="0.0" SE="0.6585302333627979" STUDY_ID="STD-PRISMS-1998" TOTAL_1="184" TOTAL_2="187" VAR="0.433662068252861" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.482639482772374" CI_END="6.131075915259395" CI_START="0.49394589051785187" DF="2" EFFECT_SIZE="1.7402355452051186" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="40" I2="42.57229294351509" ID="CMP-002.02.06" LOG_CI_END="0.7875366936144519" LOG_CI_START="-0.30632062341764144" LOG_EFFECT_SIZE="0.24060803509840528" NO="6" P_CHI2="0.1752892397388388" P_Z="0.38855615864851445" STUDIES="3" TAU2="0.608610446123322" TOTAL_1="510" TOTAL_2="514" WEIGHT="100.00000000000001" Z="0.8622387505956365">
<NAME>Glatiramer acetate 20 mg daily versus placebo</NAME>
<DICH_DATA CI_END="99.16103229177347" CI_START="0.25211516482038504" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9963410392362373" LOG_CI_START="-0.5984010305641998" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="543" O_E="0.0" SE="1.5241643359811707" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="25" VAR="2.3230769230769233" WEIGHT="14.082472135270283" />
<DICH_DATA CI_END="1.429255076337863" CI_START="0.6061418813823773" EFFECT_SIZE="0.9307692307692308" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="39" LOG_CI_END="0.15510974338874647" LOG_CI_START="-0.21742570736951977" LOG_EFFECT_SIZE="-0.031157981990386677" ORDER="94" O_E="0.0" SE="0.21882916785562778" STUDY_ID="STD-CONFIRM-2012" TOTAL_1="360" TOTAL_2="363" VAR="0.04788620470438652" WEIGHT="62.8874581980484" />
<DICH_DATA CI_END="42.52680786360582" CI_START="0.5973079400050274" EFFECT_SIZE="5.04" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.628662785035908" LOG_CI_START="-0.22380171214485756" LOG_EFFECT_SIZE="0.7024305364455253" ORDER="542" O_E="0.0" SE="1.0881468154911322" STUDY_ID="STD-Johnson-1995" TOTAL_1="125" TOTAL_2="126" VAR="1.184063492063492" WEIGHT="23.030069666681324" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5287430900520045" CI_START="0.9301009802680934" DF="0" EFFECT_SIZE="1.5336187358348023" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="19" I2="0.0" ID="CMP-002.02.07" LOG_CI_END="0.4029047090437608" LOG_CI_START="-0.031469897905776076" LOG_EFFECT_SIZE="0.1857174055689924" NO="7" P_CHI2="1.0" P_Z="0.09374404986996045" STUDIES="1" TAU2="0.0" TOTAL_1="627" TOTAL_2="315" WEIGHT="100.0" Z="1.6759700976706995">
<NAME>Natalizumab versus placebo</NAME>
<DICH_DATA CI_END="2.5287430900520045" CI_START="0.9301009802680934" EFFECT_SIZE="1.5336187358348023" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="19" LOG_CI_END="0.4029047090437608" LOG_CI_START="-0.031469897905776076" LOG_EFFECT_SIZE="0.1857174055689924" ORDER="544" O_E="0.0" SE="0.2551537943111402" STUDY_ID="STD-AFFIRM-2006" TOTAL_1="627" TOTAL_2="315" VAR="0.06510345875137163" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="168.83957675554151" CI_START="0.5713142678824412" DF="0" EFFECT_SIZE="9.821428571428573" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-002.02.08" LOG_CI_END="2.2274742548009963" LOG_CI_START="-0.24312492982490969" LOG_EFFECT_SIZE="0.9921746624880435" NO="8" P_CHI2="1.0" P_Z="0.11543785425022422" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="24" WEIGHT="100.0" Z="1.574214560541273">
<NAME>Mitoxantrone versus placebo</NAME>
<DICH_DATA CI_END="168.83957675554151" CI_START="0.5713142678824412" EFFECT_SIZE="9.821428571428571" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2274742548009963" LOG_CI_START="-0.24312492982490969" LOG_EFFECT_SIZE="0.9921746624880434" ORDER="545" O_E="0.0" SE="1.4512421907124586" STUDY_ID="STD-Millefiorini-1997" TOTAL_1="27" TOTAL_2="24" VAR="2.106103896103896" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.5848727028859417" CI_END="2.254362146067331" CI_START="0.8890257414182718" DF="1" EFFECT_SIZE="1.415692755626303" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="71" I2="61.31337535950894" ID="CMP-002.02.09" LOG_CI_END="0.35302368340718193" LOG_CI_START="-0.051085664008342926" LOG_EFFECT_SIZE="0.15096900969941948" NO="9" P_CHI2="0.10788946567628199" P_Z="0.14307798818339848" STUDIES="2" TAU2="0.06937828847986269" TOTAL_1="783" TOTAL_2="773" WEIGHT="100.0" Z="1.4644245360070223">
<NAME>Fingolimod 0.5 mg versus placebo</NAME>
<DICH_DATA CI_END="1.7111456787435524" CI_START="0.7061501858204084" EFFECT_SIZE="1.0992387543252595" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="34" LOG_CI_END="0.23328698486619331" LOG_CI_START="-0.15110292226763583" LOG_EFFECT_SIZE="0.04109203129927869" ORDER="15" O_E="0.0" SE="0.22579253421113887" STUDY_ID="STD-FREEDOMS-2010" TOTAL_1="425" TOTAL_2="418" VAR="0.05098226850548832" WEIGHT="46.81540745225806" />
<DICH_DATA CI_END="2.573128910526431" CI_START="1.2159438805497453" EFFECT_SIZE="1.7688358749811264" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="37" LOG_CI_END="0.41046154436342563" LOG_CI_START="0.08491353140876115" LOG_EFFECT_SIZE="0.2476875378860934" ORDER="152" O_E="0.0" SE="0.19122851429822385" STUDY_ID="STD-FREEDOMS-II-2014" TOTAL_1="358" TOTAL_2="355" VAR="0.036568344680706" WEIGHT="53.18459254774195" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.06933893166440853" CI_END="2.5230665093924154" CI_START="1.4793358104819843" DF="1" EFFECT_SIZE="1.9319582396035324" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="71" I2="0.0" ID="CMP-002.02.10" LOG_CI_END="0.40192869890497446" LOG_CI_START="0.1700667704032914" LOG_EFFECT_SIZE="0.2859977346541329" NO="10" P_CHI2="0.7923017420259971" P_Z="1.3303570814807935E-6" STUDIES="2" TAU2="0.0" TOTAL_1="799" TOTAL_2="773" WEIGHT="100.0" Z="4.8351642997576">
<NAME>Fingolimod 1.25 mg versus placebo</NAME>
<DICH_DATA CI_END="2.953800713506392" CI_START="1.3623698819305936" EFFECT_SIZE="2.0060331825037707" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="34" LOG_CI_END="0.4703811910625715" LOG_CI_START="0.13429503406205381" LOG_EFFECT_SIZE="0.30233811256231263" ORDER="24" O_E="0.0" SE="0.19741867227541232" STUDY_ID="STD-FREEDOMS-2010" TOTAL_1="429" TOTAL_2="418" VAR="0.038974132162986654" WEIGHT="47.5945952670555" />
<DICH_DATA CI_END="2.6996140076559665" CI_START="1.2912583109031899" EFFECT_SIZE="1.8670562454346238" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="37" LOG_CI_END="0.43130167292612565" LOG_CI_START="0.11101312977861948" LOG_EFFECT_SIZE="0.27115740135237254" ORDER="153" O_E="0.0" SE="0.18813907569870356" STUDY_ID="STD-FREEDOMS-II-2014" TOTAL_1="370" TOTAL_2="355" VAR="0.035396311804762506" WEIGHT="52.4054047329445" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9640268010810655" CI_START="0.771814041125518" DF="0" EFFECT_SIZE="1.2312040700960996" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="29" I2="0.0" ID="CMP-002.02.11" LOG_CI_END="0.293147409867529" LOG_CI_START="-0.11248732484746297" LOG_EFFECT_SIZE="0.09033004251003306" NO="11" P_CHI2="1.0" P_Z="0.3827059039780095" STUDIES="1" TAU2="0.0" TOTAL_1="366" TOTAL_2="363" WEIGHT="100.0" Z="0.8729214482385571">
<NAME>Teriflunomide 7 mg versus placebo</NAME>
<DICH_DATA CI_END="1.9640268010810655" CI_START="0.771814041125518" EFFECT_SIZE="1.2312040700960996" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="29" LOG_CI_END="0.293147409867529" LOG_CI_START="-0.11248732484746297" LOG_EFFECT_SIZE="0.09033004251003306" ORDER="39" O_E="0.0" SE="0.2382718510959065" STUDY_ID="STD-TEMSO-2011" TOTAL_1="366" TOTAL_2="363" VAR="0.05677347502466984" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1495416292547485" CI_START="0.8602243085265069" DF="0" EFFECT_SIZE="1.3598117375852463" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="29" I2="0.0" ID="CMP-002.02.12" LOG_CI_END="0.3323458603302317" LOG_CI_START="-0.06538828915955872" LOG_EFFECT_SIZE="0.13347878558533646" NO="12" P_CHI2="1.0" P_Z="0.1883352031481359" STUDIES="1" TAU2="0.0" TOTAL_1="359" TOTAL_2="363" WEIGHT="100.0" Z="1.3155199913459736">
<NAME>Teriflunomide 14 mg versus placebo</NAME>
<DICH_DATA CI_END="2.1495416292547485" CI_START="0.8602243085265069" EFFECT_SIZE="1.3598117375852463" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="29" LOG_CI_END="0.3323458603302317" LOG_CI_START="-0.06538828915955872" LOG_EFFECT_SIZE="0.13347878558533646" ORDER="253" O_E="0.0" SE="0.23363100822609553" STUDY_ID="STD-TEMSO-2011" TOTAL_1="359" TOTAL_2="363" VAR="0.054583448004741915" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.04477556750715714" CI_END="1.5123293202545784" CI_START="0.9057624060589458" DF="1" EFFECT_SIZE="1.1703892702290453" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="94" I2="0.0" ID="CMP-002.02.13" LOG_CI_END="0.17964637211505308" LOG_CI_START="-0.04298570880207174" LOG_EFFECT_SIZE="0.06833033165649072" NO="13" P_CHI2="0.8324173937314157" P_Z="0.22893535040458046" STUDIES="2" TAU2="0.0" TOTAL_1="773" TOTAL_2="773" WEIGHT="100.0" Z="1.203105936455337">
<NAME>Dimethyl fumarate 480 mg versus placebo</NAME>
<DICH_DATA CI_END="1.6974189683616734" CI_START="0.7540205754234257" EFFECT_SIZE="1.1313217169570762" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="39" LOG_CI_END="0.22978905103303282" LOG_CI_START="-0.12261680310776274" LOG_EFFECT_SIZE="0.053586123962635075" ORDER="256" O_E="0.0" SE="0.20700494315941523" STUDY_ID="STD-CONFIRM-2012" TOTAL_1="362" TOTAL_2="363" VAR="0.04285104649243273" WEIGHT="39.91069243789866" />
<DICH_DATA CI_END="1.6661912075400493" CI_START="0.8600460853112855" EFFECT_SIZE="1.197080291970803" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="55" LOG_CI_END="0.2217248383760606" LOG_CI_START="-0.0654782765934783" LOG_EFFECT_SIZE="0.07812328089129116" ORDER="255" O_E="0.0" SE="0.16870453141145478" STUDY_ID="STD-DEFINE-2012" TOTAL_1="411" TOTAL_2="410" VAR="0.02846121891875853" WEIGHT="60.08930756210134" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.1063758959066137" CI_END="1.5434385919428242" CI_START="0.9255682073925824" DF="1" EFFECT_SIZE="1.1952228623838532" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="94" I2="0.0" ID="CMP-002.02.14" LOG_CI_END="0.18848935509384737" LOG_CI_START="-0.03359157150563751" LOG_EFFECT_SIZE="0.07744889179410494" NO="14" P_CHI2="0.7443084978784505" P_Z="0.17161196759069225" STUDIES="2" TAU2="0.0" TOTAL_1="761" TOTAL_2="773" WEIGHT="100.0" Z="1.3670425541113311">
<NAME>Dimethyl fumarate 720 mg versus placebo</NAME>
<DICH_DATA CI_END="1.7076928474838051" CI_START="0.7518559954844181" EFFECT_SIZE="1.1331103678929766" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="39" LOG_CI_END="0.2324097594217123" LOG_CI_START="-0.12386533275323297" LOG_EFFECT_SIZE="0.054272213334239656" ORDER="20" O_E="0.0" SE="0.20927775273371188" STUDY_ID="STD-CONFIRM-2012" TOTAL_1="345" TOTAL_2="363" VAR="0.04379717778927265" WEIGHT="38.855419252638754" />
<DICH_DATA CI_END="1.714673688504401" CI_START="0.89160474479878" EFFECT_SIZE="1.236451048951049" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="55" LOG_CI_END="0.23418148369911013" LOG_CI_START="-0.04982762902710168" LOG_EFFECT_SIZE="0.09217692733600422" ORDER="21" O_E="0.0" SE="0.16682835868315835" STUDY_ID="STD-DEFINE-2012" TOTAL_1="416" TOTAL_2="410" VAR="0.027831701260916535" WEIGHT="61.14458074736124" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3648054507125556" CI_END="2.0049605576773675" CI_START="0.9630222073932698" DF="1" EFFECT_SIZE="1.3895400469187276" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="47" I2="0.0" ID="CMP-002.02.15" LOG_CI_END="0.3021058334392129" LOG_CI_START="-0.0163636978836155" LOG_EFFECT_SIZE="0.14287106777779868" NO="15" P_CHI2="0.5458497050081031" P_Z="0.07865413190618552" STUDIES="2" TAU2="0.0" TOTAL_1="984" TOTAL_2="1006" WEIGHT="100.0" Z="1.7585490587695292">
<NAME>Laquinimod versus placebo</NAME>
<DICH_DATA CI_END="2.410278358800776" CI_START="0.9539805513708329" EFFECT_SIZE="1.5163636363636364" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="28" LOG_CI_END="0.3820672013757932" LOG_CI_START="-0.02046047908880342" LOG_EFFECT_SIZE="0.18080336114349488" ORDER="65" O_E="0.0" SE="0.23644675204905768" STUDY_ID="STD-ALLEGRO-2012" TOTAL_1="550" TOTAL_2="556" VAR="0.055907066554548565" WEIGHT="62.59566766727124" />
<DICH_DATA CI_END="2.1865200738353043" CI_START="0.6592198247245689" EFFECT_SIZE="1.2005821004123212" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="19" LOG_CI_END="0.3397534688365514" LOG_CI_START="-0.1809697405721309" LOG_EFFECT_SIZE="0.07939186413221026" ORDER="139" O_E="0.0" SE="0.3058753908281179" STUDY_ID="STD-BRAVO-2014" TOTAL_1="434" TOTAL_2="450" VAR="0.09355975471425386" WEIGHT="37.40433233272876" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="45.25943742724042" CI_START="0.7432703964577563" DF="0" EFFECT_SIZE="5.8" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-002.02.16" LOG_CI_END="1.655709151391498" LOG_CI_START="-0.12885316426562343" LOG_EFFECT_SIZE="0.7634279935629372" NO="16" P_CHI2="1.0" P_Z="0.0935565369117186" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="29" WEIGHT="100.0" Z="1.6769281285894024">
<NAME>Azathioprine versus placebo</NAME>
<DICH_DATA CI_END="45.25943742724042" CI_START="0.7432703964577563" EFFECT_SIZE="5.8" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.655709151391498" LOG_CI_START="-0.12885316426562343" LOG_EFFECT_SIZE="0.7634279935629372" ORDER="546" O_E="0.0" SE="1.048260737942924" STUDY_ID="STD-Goodkin-1991" TOTAL_1="30" TOTAL_2="29" VAR="1.0988505747126436" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="28.19198556232095" CI_START="0.3192396640564633" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-002.02.17" LOG_CI_END="1.45012566432113" LOG_CI_START="-0.4958831548818049" LOG_EFFECT_SIZE="0.47712125471966244" NO="17" P_CHI2="1.0" P_Z="0.33650916798205566" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="75" WEIGHT="100.0" Z="0.9610855472814597">
<NAME>Immunoglobulins 0.15 to 0.20 g versus placebo</NAME>
<DICH_DATA CI_END="28.19198556232095" CI_START="0.3192396640564633" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.45012566432113" LOG_CI_START="-0.4958831548818049" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="165" O_E="0.0" SE="1.1430952132988164" STUDY_ID="STD-Fazekas-1997" TOTAL_1="75" TOTAL_2="75" VAR="1.3066666666666664" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7524711356768206" CI_START="0.024852834577200604" DF="0" EFFECT_SIZE="0.20869565217391306" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-002.02.18" LOG_CI_END="0.24365087358904436" LOG_CI_START="-1.6046240708730557" LOG_EFFECT_SIZE="-0.6804865986420057" NO="18" P_CHI2="1.0" P_Z="0.1489598655546514" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="96" WEIGHT="100.0" Z="1.443215176721066">
<NAME>Interferon beta-1a (Avonex) 30 µg versus interferon beta-1b (Betaseron) 250 µg</NAME>
<DICH_DATA CI_END="1.7524711356768206" CI_START="0.024852834577200604" EFFECT_SIZE="0.20869565217391303" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.24365087358904436" LOG_CI_START="-1.6046240708730557" LOG_EFFECT_SIZE="-0.6804865986420057" ORDER="549" O_E="0.0" SE="1.0856858514855676" STUDY_ID="STD-INCOMIN-2002" TOTAL_1="92" TOTAL_2="96" VAR="1.1787137681159419" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6837154890588797" CI_END="2.530567310568829" CI_START="0.5563687260916304" DF="1" EFFECT_SIZE="1.1865616338270433" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" I2="0.0" ID="CMP-002.02.19" LOG_CI_END="0.4032178935988999" LOG_CI_START="-0.25463729001635893" LOG_EFFECT_SIZE="0.07429030179127048" NO="19" P_CHI2="0.40831060859304424" P_Z="0.6580045806186683" STUDIES="2" TAU2="0.0" TOTAL_1="487" TOTAL_2="933" WEIGHT="100.0" Z="0.4426698140807179">
<NAME>Glatiramer acetate 20 mg daily versus interferon beta-1b (Betaseron) 250 μg</NAME>
<DICH_DATA CI_END="3.474291818016567" CI_START="0.10900011993473406" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5408662935675301" LOG_CI_START="-0.9625730241973164" LOG_EFFECT_SIZE="-0.21085336531489315" ORDER="82" O_E="0.0" SE="0.8831276973997191" STUDY_ID="STD-BECOME-2009" TOTAL_1="39" TOTAL_2="36" VAR="0.7799145299145298" WEIGHT="19.146473493262068" />
<DICH_DATA CI_END="3.2182485632080056" CI_START="0.5970457185301298" EFFECT_SIZE="1.3861607142857142" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.5076195840329794" LOG_CI_START="-0.223992411676107" LOG_EFFECT_SIZE="0.14181358617843615" ORDER="552" O_E="0.0" SE="0.42975250781730345" STUDY_ID="STD-BEYOND-2009" TOTAL_1="448" TOTAL_2="897" VAR="0.18468721797526147" WEIGHT="80.85352650673794" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6827920870339468" CI_START="0.3664057168548762" DF="0" EFFECT_SIZE="0.7852290372670807" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="23" I2="0.0" ID="CMP-002.02.20" LOG_CI_END="0.2260304611738319" LOG_CI_START="-0.43603775886019835" LOG_EFFECT_SIZE="-0.10500364884318326" NO="20" P_CHI2="1.0" P_Z="0.5341402204616517" STUDIES="1" TAU2="0.0" TOTAL_1="448" TOTAL_2="899" WEIGHT="100.0" Z="0.6216983801679887">
<NAME>Glatiramer acetate 20 mg daily versus interferon beta-1b (Betaseron) 500 μg</NAME>
<DICH_DATA CI_END="1.6827920870339468" CI_START="0.3664057168548762" EFFECT_SIZE="0.7852290372670807" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="23" LOG_CI_END="0.2260304611738319" LOG_CI_START="-0.43603775886019835" LOG_EFFECT_SIZE="-0.10500364884318326" ORDER="148" O_E="0.0" SE="0.38890214973853404" STUDY_ID="STD-BEYOND-2009" TOTAL_1="448" TOTAL_2="899" VAR="0.15124488207125317" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.11934885000677E-31" CI_END="1.5230640910860005" CI_START="0.4672231580307055" DF="0" EFFECT_SIZE="0.843570278352887" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" I2="100.0" ID="CMP-002.02.21" LOG_CI_END="0.18271817898892512" LOG_CI_START="-0.33047563944939373" LOG_EFFECT_SIZE="-0.07387873023023432" NO="21" P_CHI2="0.0" P_Z="0.5725446417596007" STUDIES="1" TAU2="0.0" TOTAL_1="378" TOTAL_2="386" WEIGHT="100.00000000000001" Z="0.5643078512342347">
<NAME>Glatiramer acetate 20 mg daily versus interferon beta-1a (Rebif) 44 µg</NAME>
<DICH_DATA CI_END="1.5230640910860005" CI_START="0.4672231580307055" EFFECT_SIZE="0.843570278352887" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.18271817898892512" LOG_CI_START="-0.33047563944939373" LOG_EFFECT_SIZE="-0.07387873023023432" ORDER="553" O_E="0.0" SE="0.30145258930103996" STUDY_ID="STD-REGARD-2008" TOTAL_1="378" TOTAL_2="386" VAR="0.09087366359630146" WEIGHT="100.00000000000001" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.841792368851861" CI_START="0.8021351406068485" DF="0" EFFECT_SIZE="1.2154696132596685" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="36" I2="0.0" ID="CMP-002.02.22" LOG_CI_END="0.26524066921345446" LOG_CI_START="-0.095752457307411" LOG_EFFECT_SIZE="0.08474410595302173" NO="22" P_CHI2="1.0" P_Z="0.357461149790154" STUDIES="1" TAU2="0.0" TOTAL_1="362" TOTAL_2="360" WEIGHT="99.99999999999999" Z="0.9202136183075977">
<NAME>Dimethyl fumarate 480 mg versus glatiramer acetate 20 mg daily</NAME>
<DICH_DATA CI_END="1.841792368851861" CI_START="0.8021351406068485" EFFECT_SIZE="1.2154696132596685" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="36" LOG_CI_END="0.26524066921345446" LOG_CI_START="-0.095752457307411" LOG_EFFECT_SIZE="0.08474410595302173" ORDER="92" O_E="0.0" SE="0.2120491494631521" STUDY_ID="STD-CONFIRM-2012" TOTAL_1="362" TOTAL_2="360" VAR="0.04496484178804621" WEIGHT="99.99999999999999" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.852745808404232" CI_START="0.7999163086371693" DF="0" EFFECT_SIZE="1.2173913043478262" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="36" I2="0.0" ID="CMP-002.02.23" LOG_CI_END="0.2678158394052883" LOG_CI_START="-0.09695544875603555" LOG_EFFECT_SIZE="0.08543019532462637" NO="23" P_CHI2="1.0" P_Z="0.35858992910375675" STUDIES="1" TAU2="0.0" TOTAL_1="345" TOTAL_2="360" WEIGHT="100.0" Z="0.9180552936196981">
<NAME>Dimethyl fumarate 720 mg versus glatiramer acetate 20 mg daily</NAME>
<DICH_DATA CI_END="1.852745808404232" CI_START="0.7999163086371693" EFFECT_SIZE="1.2173913043478262" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="36" LOG_CI_END="0.2678158394052883" LOG_CI_START="-0.09695544875603555" LOG_EFFECT_SIZE="0.08543019532462637" ORDER="93" O_E="0.0" SE="0.2142684603129591" STUDY_ID="STD-CONFIRM-2012" TOTAL_1="345" TOTAL_2="360" VAR="0.04591097308488613" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.3728526603171916" CI_END="0.6796795232613744" CI_START="0.21657653654850315" DF="2" EFFECT_SIZE="0.38366995857232067" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="39" I2="15.71326642200154" ID="CMP-002.02.24" LOG_CI_END="-0.1676958138919947" LOG_CI_START="-0.6643885957230522" LOG_EFFECT_SIZE="-0.41604220480752346" NO="24" P_CHI2="0.30531045095965614" P_Z="0.0010255248011390948" STUDIES="3" TAU2="0.04308381062359504" TOTAL_1="935" TOTAL_2="537" WEIGHT="100.00000000000001" Z="3.2834289818559848">
<NAME>Alemtuzumab 12 mg versus interferon beta-1a (Rebif) 44 µg</NAME>
<DICH_DATA CI_END="0.773800976457246" CI_START="0.06640726621294107" EFFECT_SIZE="0.2266848196051736" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" LOG_CI_END="-0.11137072657945958" LOG_CI_START="-1.1777843979884137" LOG_EFFECT_SIZE="-0.6445775622839366" ORDER="49" O_E="0.0" SE="0.626416669418429" STUDY_ID="STD-CAMMS223-2008" TOTAL_1="113" TOTAL_2="111" VAR="0.3923978437252773" WEIGHT="19.547041602558597" />
<DICH_DATA CI_END="0.7339809718486472" CI_START="0.10344915383039548" EFFECT_SIZE="0.27555346208195947" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="-0.1343151988417639" LOG_CI_START="-0.9852730573258729" LOG_EFFECT_SIZE="-0.5597941280838183" ORDER="31" O_E="0.0" SE="0.49985685838290034" STUDY_ID="STD-CARE_x002d_MS-I-2012" TOTAL_1="386" TOTAL_2="195" VAR="0.2498568788724229" WEIGHT="29.058366829658752" />
<DICH_DATA CI_END="1.1223501170717494" CI_START="0.28456407556514607" EFFECT_SIZE="0.5651376146788991" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.050128356201077175" LOG_CI_START="-0.5458199277534735" LOG_EFFECT_SIZE="-0.24784578577619815" ORDER="36" O_E="0.0" SE="0.3500629719864855" STUDY_ID="STD-CARE_x002d_MS-II-2012" TOTAL_1="436" TOTAL_2="231" VAR="0.12254408435601095" WEIGHT="51.39459156778266" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9999664456481892" CI_END="1.0883329951309353" CI_START="0.0993162222196706" DF="1" EFFECT_SIZE="0.32876910072788723" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="28" I2="49.99916112713081" ID="CMP-002.02.25" LOG_CI_END="0.03676179593327587" LOG_CI_START="-1.0029798084524946" LOG_EFFECT_SIZE="-0.4831090062596093" NO="25" P_CHI2="0.15730304765959613" P_Z="0.06855087483584768" STUDIES="2" TAU2="0.39101044996088824" TOTAL_1="283" TOTAL_2="342" WEIGHT="99.99999999999999" Z="1.8213684032296449">
<NAME>Alemtuzumab 24 mg versus interferon beta-1a (Rebif) 44 µg</NAME>
<DICH_DATA CI_END="0.6719364259018443" CI_START="0.03586787842117165" EFFECT_SIZE="0.15524475524475526" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="13" LOG_CI_END="-0.17267181502074355" LOG_CI_START="-1.4452943110081027" LOG_EFFECT_SIZE="-0.8089830630144231" ORDER="50" O_E="0.0" SE="0.7475447537259283" STUDY_ID="STD-CAMMS223-2008" TOTAL_1="110" TOTAL_2="111" VAR="0.5588231588231588" WEIGHT="39.2715927997473" />
<DICH_DATA CI_END="1.348309303513727" CI_START="0.21157395522636435" EFFECT_SIZE="0.5341040462427745" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="0.12978953122043194" LOG_CI_START="-0.6745377950378095" LOG_EFFECT_SIZE="-0.27237413190868875" ORDER="259" O_E="0.0" SE="0.4724658529285686" STUDY_ID="STD-CARE_x002d_MS-II-2012" TOTAL_1="173" TOTAL_2="231" VAR="0.22322398218351977" WEIGHT="60.72840720025268" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.450536334525799" CI_START="0.4855397704212299" DF="0" EFFECT_SIZE="0.8392217101894521" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="27" I2="0.0" ID="CMP-002.02.26" LOG_CI_END="0.16152861192973433" LOG_CI_START="-0.31377519136444487" LOG_EFFECT_SIZE="-0.0761232897173553" NO="26" P_CHI2="1.0" P_Z="0.530132096051799" STUDIES="1" TAU2="0.0" TOTAL_1="434" TOTAL_2="447" WEIGHT="100.0" Z="0.6278043861491305">
<NAME>Laquinimod versus interferon beta-1a (Avonex) 30 µg</NAME>
<DICH_DATA CI_END="1.450536334525799" CI_START="0.4855397704212299" EFFECT_SIZE="0.8392217101894521" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="27" LOG_CI_END="0.16152861192973433" LOG_CI_START="-0.31377519136444487" LOG_EFFECT_SIZE="-0.0761232897173553" ORDER="141" O_E="0.0" SE="0.27919580684677253" STUDY_ID="STD-BRAVO-2014" TOTAL_1="434" TOTAL_2="447" VAR="0.07795029856082031" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.447351804949646" CI_START="0.8983227873533414" DF="0" EFFECT_SIZE="2.212121212121212" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" I2="0.0" ID="CMP-002.02.27" LOG_CI_END="0.7361854241100204" LOG_CI_START="-0.04656758362488354" LOG_EFFECT_SIZE="0.3448089202425684" NO="27" P_CHI2="1.0" P_Z="0.08421087902394885" STUDIES="1" TAU2="0.0" TOTAL_1="77" TOTAL_2="73" WEIGHT="100.00000000000001" Z="1.7267594210317152">
<NAME>Azathioprine versus interferons beta (Avonex, Rebif or Betaseron)</NAME>
<DICH_DATA CI_END="5.447351804949646" CI_START="0.8983227873533414" EFFECT_SIZE="2.212121212121212" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7361854241100204" LOG_CI_START="-0.04656758362488354" LOG_EFFECT_SIZE="0.3448089202425684" ORDER="181" O_E="0.0" SE="0.459792991433361" STUDY_ID="STD-MAIN-TRIAL" TOTAL_1="77" TOTAL_2="73" VAR="0.2114095949712388" WEIGHT="100.00000000000001" />
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Treatment safety against placebo within pairwise comparisons</NAME>
<DICH_OUTCOME CHI2="13.956058278144795" CI_END="1.2693541343097487" CI_START="0.958130226639096" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1028175571650431" ESTIMABLE="YES" EVENTS_1="506" EVENTS_2="427" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.10358280185878538" LOG_CI_START="-0.018575458701143015" LOG_EFFECT_SIZE="0.04250367157882121" METHOD="MH" NO="1" P_CHI2="0.5288644163271488" P_Q="0.8619216362648007" P_Z="0.17259986687580373" Q="4.671890441854705" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="4974" TOTAL_2="4642" WEIGHT="1000.0" Z="1.3638973758035815">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.2812875242491" CI_END="2.3683782469454093" CI_START="0.6673749772253565" DF="2" EFFECT_SIZE="1.2572177132924203" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="42" I2="53.285080979213554" ID="CMP-003.01.01" LOG_CI_END="0.3744510635250789" LOG_CI_START="-0.17563008095464105" LOG_EFFECT_SIZE="0.09941049128521891" NO="1" P_CHI2="0.11757919229834235" P_Z="0.4786918386369564" STUDIES="3" TAU2="0.16158308196719884" TOTAL_1="440" TOTAL_2="430" WEIGHT="100.0" Z="0.7084081487241207">
<NAME>Interferons beta (Avonex, Rebif or Betaseron) versus placebo</NAME>
<DICH_DATA CI_END="2.986096503158959" CI_START="0.8747380296283667" EFFECT_SIZE="1.6161844484629295" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="14" LOG_CI_END="0.47510383892557356" LOG_CI_START="-0.05812199191669602" LOG_EFFECT_SIZE="0.2084909235044388" ORDER="164" O_E="0.0" SE="0.31321949254718134" STUDY_ID="STD-MSCRG-1996" TOTAL_1="158" TOTAL_2="143" VAR="0.0981064505115138" WEIGHT="40.204464013664754" />
<DICH_DATA CI_END="8.944160265145097" CI_START="0.6338140275118213" EFFECT_SIZE="2.380952380952381" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9515395724793531" LOG_CI_START="-0.19803815327515387" LOG_EFFECT_SIZE="0.37675070960209955" ORDER="166" O_E="0.0" SE="0.675267646609715" STUDY_ID="STD-OWIMS-1999" TOTAL_1="98" TOTAL_2="100" VAR="0.4559863945578231" WEIGHT="16.906079170256405" />
<DICH_DATA CI_END="1.353194350893585" CI_START="0.44087408925272087" EFFECT_SIZE="0.7723913043478261" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="25" LOG_CI_END="0.13136017609431672" LOG_CI_START="-0.35568542447880896" LOG_EFFECT_SIZE="-0.11216262419224614" ORDER="167" O_E="0.0" SE="0.2860929966912596" STUDY_ID="STD-PRISMS-1998" TOTAL_1="184" TOTAL_2="187" VAR="0.08184920275578508" WEIGHT="42.889456816078834" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4644815344156015" CI_END="4.737880978903323" CI_START="0.7343177017199425" DF="1" EFFECT_SIZE="1.865237215865832" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.6755841465398129" LOG_CI_START="-0.13411600241096705" LOG_EFFECT_SIZE="0.27073407206442296" NO="2" P_CHI2="0.4955369693106828" P_Z="0.18996578572305786" STUDIES="2" TAU2="0.0" TOTAL_1="244" TOTAL_2="246" WEIGHT="100.0" Z="1.3106803335079944">
<NAME>Glatiramer acetate versus placebo</NAME>
<DICH_DATA CI_END="4.477382461620494" CI_START="0.6308729039092564" EFFECT_SIZE="1.680672268907563" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6510241937528619" LOG_CI_START="-0.20005812520996097" LOG_EFFECT_SIZE="0.22548303427145044" ORDER="163" O_E="0.0" SE="0.4999299670841862" STUDY_ID="STD-Comi-2001" TOTAL_1="119" TOTAL_2="120" VAR="0.2499299719887955" WEIGHT="90.51182086105888" />
<DICH_DATA CI_END="103.92696180303943" CI_START="0.24438701622891337" EFFECT_SIZE="5.0396825396825395" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0167282313230017" LOG_CI_START="-0.6119218709741759" LOG_EFFECT_SIZE="0.7024031801744127" ORDER="168" O_E="0.0" SE="1.5440820821172236" STUDY_ID="STD-Johnson-1995" TOTAL_1="125" TOTAL_2="126" VAR="2.3841894763154605" WEIGHT="9.488179138941128" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7279485210399173" CI_START="0.8133088726649198" DF="0" EFFECT_SIZE="1.1854770616380523" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="34" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="0.23753079985507095" LOG_CI_START="-0.089744489806829" LOG_EFFECT_SIZE="0.07389315502412097" NO="3" P_CHI2="1.0" P_Z="0.37612827369397184" STUDIES="1" TAU2="0.0" TOTAL_1="627" TOTAL_2="312" WEIGHT="100.0" Z="0.8850525971632641">
<NAME>Natalizumab versus placebo</NAME>
<DICH_DATA CI_END="1.7279485210399173" CI_START="0.8133088726649198" EFFECT_SIZE="1.1854770616380523" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="34" LOG_CI_END="0.23753079985507095" LOG_CI_START="-0.089744489806829" LOG_EFFECT_SIZE="0.07389315502412097" ORDER="170" O_E="0.0" SE="0.1922431251862115" STUDY_ID="STD-AFFIRM-2006" TOTAL_1="627" TOTAL_2="312" VAR="0.03695741918136139" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3034062021438553" CI_END="1.2994865018785278" CI_START="0.7227067437807565" DF="1" EFFECT_SIZE="0.9690963101568785" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="102" I2="23.277946786259708" ID="CMP-003.01.04" LOG_CI_END="0.11377177272497502" LOG_CI_START="-0.14103789273860826" LOG_EFFECT_SIZE="-0.013633060006816605" NO="4" P_CHI2="0.2535921008974894" P_Z="0.8338803025352081" STUDIES="2" TAU2="0.010437054831937099" TOTAL_1="799" TOTAL_2="773" WEIGHT="99.99999999999999" Z="0.20972757500247">
<NAME>Fingolimod versus placebo</NAME>
<DICH_DATA CI_END="1.1973013802959722" CI_START="0.5859721085699373" EFFECT_SIZE="0.8376068376068376" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="57" LOG_CI_END="0.07820348317567984" LOG_CI_START="-0.2321230552830134" LOG_EFFECT_SIZE="-0.07695978605366678" ORDER="220" O_E="0.0" SE="0.18228734483177636" STUDY_ID="STD-FREEDOMS-2010" TOTAL_1="429" TOTAL_2="418" VAR="0.03322867608581894" WEIGHT="51.305776531117" />
<DICH_DATA CI_END="1.6354147510308878" CI_START="0.7808220318208154" EFFECT_SIZE="1.13003003003003" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="45" LOG_CI_END="0.21362791066105774" LOG_CI_START="-0.10744794103396871" LOG_EFFECT_SIZE="0.05308998481354449" ORDER="221" O_E="0.0" SE="0.18860154463675716" STUDY_ID="STD-FREEDOMS-II-2014" TOTAL_1="370" TOTAL_2="355" VAR="0.0355705426393707" WEIGHT="48.69422346888299" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8335983357698422" CI_START="0.869731802308874" DF="0" EFFECT_SIZE="1.2628296738989218" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="43" I2="0.0" ID="CMP-003.01.05" LOG_CI_END="0.2633042061084662" LOG_CI_START="-0.06061464937487648" LOG_EFFECT_SIZE="0.10134477836679491" NO="5" P_CHI2="1.0" P_Z="0.22003642694569892" STUDIES="1" TAU2="0.0" TOTAL_1="358" TOTAL_2="360" WEIGHT="100.0" Z="1.2264313253621417">
<NAME>Teriflunomide versus placebo</NAME>
<DICH_DATA CI_END="1.8335983357698422" CI_START="0.869731802308874" EFFECT_SIZE="1.2628296738989218" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="43" LOG_CI_END="0.2633042061084662" LOG_CI_START="-0.06061464937487648" LOG_EFFECT_SIZE="0.10134477836679491" ORDER="222" O_E="0.0" SE="0.19027153913510986" STUDY_ID="STD-TEMSO-2011" TOTAL_1="358" TOTAL_2="360" VAR="0.03620325860484364" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8950216123037045" CI_END="1.552919014489397" CI_START="0.762745329700243" DF="1" EFFECT_SIZE="1.0883389755515014" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="55" I2="0.0" ID="CMP-003.01.06" LOG_CI_END="0.19114880764262138" LOG_CI_START="-0.11762044286827956" LOG_EFFECT_SIZE="0.036764182387170906" NO="6" P_CHI2="0.34412023224196775" P_Z="0.6406905746855079" STUDIES="2" TAU2="0.0" TOTAL_1="760" TOTAL_2="771" WEIGHT="100.0" Z="0.46673347997373127">
<NAME>Dimethyl fumarate versus placebo</NAME>
<DICH_DATA CI_END="1.5212208640313514" CI_START="0.5439864889411116" EFFECT_SIZE="0.9096832397754611" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="29" LOG_CI_END="0.18219227326830353" LOG_CI_START="-0.2644118867929757" LOG_EFFECT_SIZE="-0.041109806762336096" ORDER="224" O_E="0.0" SE="0.2623374943462419" STUDY_ID="STD-CONFIRM-2012" TOTAL_1="344" TOTAL_2="363" VAR="0.06882096093986448" WEIGHT="47.79941251806785" />
<DICH_DATA CI_END="2.0977494724539665" CI_START="0.784135620068193" EFFECT_SIZE="1.282544378698225" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="26" LOG_CI_END="0.3217536205460374" LOG_CI_START="-0.10560881747688859" LOG_EFFECT_SIZE="0.10807240153457438" ORDER="223" O_E="0.0" SE="0.25103481157285296" STUDY_ID="STD-DEFINE-2012" TOTAL_1="416" TOTAL_2="408" VAR="0.0630184766214178" WEIGHT="52.20058748193216" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6766116130851698" CI_START="0.5688105157827059" DF="0" EFFECT_SIZE="0.9765625" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="25" I2="0.0" ID="CMP-003.01.07" LOG_CI_END="0.22443246998286714" LOG_CI_START="-0.24503238326249105" LOG_EFFECT_SIZE="-0.010299956639811952" NO="7" P_CHI2="1.0" P_Z="0.9314645364385432" STUDIES="1" TAU2="0.0" TOTAL_1="512" TOTAL_2="500" WEIGHT="100.0" Z="0.0860023659569034">
<NAME>Pegylated interferon beta-1a versus placebo</NAME>
<DICH_DATA CI_END="1.6766116130851698" CI_START="0.5688105157827059" EFFECT_SIZE="0.9765625" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="25" LOG_CI_END="0.22443246998286714" LOG_CI_START="-0.24503238326249105" LOG_EFFECT_SIZE="-0.010299956639811952" ORDER="225" O_E="0.0" SE="0.27576597868482616" STUDY_ID="STD-ADVANCE-2014" TOTAL_1="512" TOTAL_2="500" VAR="0.076046875" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.760944916361867E-32" CI_END="3.101246319403783" CI_START="0.7701515797446534" DF="0" EFFECT_SIZE="1.5454545454545454" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="12" I2="100.0" ID="CMP-003.01.08" LOG_CI_END="0.4915362618546869" LOG_CI_START="-0.11342378941458917" LOG_EFFECT_SIZE="0.18905623622004888" NO="8" P_CHI2="0.0" P_Z="0.2205685388667742" STUDIES="1" TAU2="0.0" TOTAL_1="209" TOTAL_2="204" WEIGHT="100.0" Z="1.2250177950314232">
<NAME>Daclizumab versus placebo</NAME>
<DICH_DATA CI_END="3.101246319403783" CI_START="0.7701515797446534" EFFECT_SIZE="1.5454545454545454" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="12" LOG_CI_END="0.4915362618546869" LOG_CI_START="-0.11342378941458917" LOG_EFFECT_SIZE="0.18905623622004888" ORDER="226" O_E="0.0" SE="0.3553565287161229" STUDY_ID="STD-SELECT-2013" TOTAL_1="209" TOTAL_2="204" VAR="0.1262782625011727" WEIGHT="100.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9977381539913264" CI_END="1.4087504017637755" CI_START="0.6729879367818791" DF="1" EFFECT_SIZE="0.9736899025478525" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="105" I2="49.94338982803741" ID="CMP-003.01.09" LOG_CI_END="0.14883405291131707" LOG_CI_START="-0.17199272037634666" LOG_EFFECT_SIZE="-0.011579333732514806" NO="9" P_CHI2="0.15753448856955665" P_Z="0.8874917873520743" STUDIES="2" TAU2="0.035588697912212926" TOTAL_1="983" TOTAL_2="1005" WEIGHT="100.0" Z="0.1414786979785484">
<NAME>Laquinimod versus placebo</NAME>
<DICH_DATA CI_END="1.648867525804296" CI_START="0.8210060742318084" EFFECT_SIZE="1.1634991423670669" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="53" LOG_CI_END="0.2171857647268154" LOG_CI_START="-0.08565362973123221" LOG_EFFECT_SIZE="0.0657660674977916" ORDER="227" O_E="0.0" SE="0.17788935938383654" STUDY_ID="STD-ALLEGRO-2012" TOTAL_1="550" TOTAL_2="556" VAR="0.03164462418199175" WEIGHT="52.824067586460465" />
<DICH_DATA CI_END="1.1786999281218655" CI_START="0.5397926013755245" EFFECT_SIZE="0.7976550008882572" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="52" LOG_CI_END="0.07140325704781866" LOG_CI_START="-0.26777307236157677" LOG_EFFECT_SIZE="-0.09818490765687903" ORDER="228" O_E="0.0" SE="0.1992338548449872" STUDY_ID="STD-BRAVO-2014" TOTAL_1="433" TOTAL_2="449" VAR="0.03969412891639343" WEIGHT="47.175932413539535" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6955063508347514" CI_START="0.11460740036819574" DF="0" EFFECT_SIZE="0.6507936507936508" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-003.01.10" LOG_CI_END="0.5676739529628488" LOG_CI_START="-0.9407873384305412" LOG_EFFECT_SIZE="-0.1865566927338462" NO="10" P_CHI2="1.0" P_Z="0.6278244494490287" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="41" WEIGHT="100.0" Z="0.4847912252299059">
<NAME>Immunoglobulins versus placebo</NAME>
<DICH_DATA CI_END="3.6955063508347514" CI_START="0.11460740036819574" EFFECT_SIZE="0.6507936507936508" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5676739529628488" LOG_CI_START="-0.9407873384305412" LOG_EFFECT_SIZE="-0.1865566927338462" ORDER="173" O_E="0.0" SE="0.8860776295682959" STUDY_ID="STD-Fazekas-2008" TOTAL_1="42" TOTAL_2="41" VAR="0.7851335656213704" WEIGHT="100.0" />
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES />
<FEEDBACK />
<APPENDICES />
<EXTENSIONS />
</COCHRANE_REVIEW>
